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Graphical Abstract: 
          
Abstract: A series of azetidin-2-ones substituted at positions 2, 3 and 4 of the azetidinone ring scaffold 
were synthesised and evaluated for antiproliferative, cytotoxic and tubulin binding activity. In these 
compounds, the cis double bond of the vascular targeting agent combretastatin A-4 is replaced with the 
azetidinone ring in order to enhance the antiproliferative effects displayed by combretastatin A-4 and 
prevent the cis/trans isomerization that is associated with inactivation of combretastatin A-4. The series 
of azetidinones was synthetically accessible via the Staudinger and Reformatsky reactions. Of a diverse 
range of heterocyclic derivatives, 3-(2-thienyl) analogue 28 and 3-(3-thienyl) analogue 29 displayed the 
highest potency in human MCF-7 breast cancer cells with IC50 values of 7nM and 10nM respectively, 
comparable to combretastatin A-4. Compounds from this series also exhibited potent activity in MDA-
MB-231 breast cancer cells and in the NCI60 cell line panel. No significant toxicity was observed in 
normal murine breast epithelial cells. The presence of larger, bulkier groups at the 3-position, for 
example 3-naphthyl derivative 21 and 3-benzothienyl derivative 26, resulted in relatively lower 
antiproliferative activity in the micromolar range. Tubulin-binding studies of 28 (IC50=1.37μM) 
confirmed that the molecular target of this series of compounds is tubulin. These novel 3-(thienyl) β-
lactam antiproliferative agents are useful scaffolds for the development of tubulin-targeting drugs. 
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Abbreviations 
BBB   Blood-brain barrier 
CA-4   Combretastatin A-4 
CA-4P   Combretastatin A-4 phosphate 
DAMA-colchicine N-Deacetyl-N-(2-mercaptoacetyl)-colchicine 
DCM   Dichloromethane 
GTP   Guanidine triphosphate 
HRMS              High Resolution Molecular Ion Determination 
IR              Infra Red 
LDA   Lithium diisopropylamide 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NCI   National Cancer Institute 
NMR   Nuclear magnetic resonance 
SAR                 Structure-Activity Relationship 
TBAF   Tetrabutylammonium fluoride 
TBDMS  tert-Butyldimethylchlorosilane 
TLC   Thin layer chromatography 
THF   Tetrahydrofuran 
TMCS   Trimethylchlorosilane 
TMS   Tetramethylsilane 
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1. Introduction 
The mitotic phase of cell division relies on assembly of the mitotic spindle. Microtubules are the main 
constituent of the mitotic spindle and are composed of the α-β heterodimeric protein tubulin.1 They are 
highly dynamic structures that alternate between periods of growing and shrinking through the addition 
or removal of tubulin subunits at the ends of microtubules.2 Microtubules are a highly-validated target in 
cancer therapy and a large number of chemically diverse substances bind to tubulin and alter 
microtubule polymerization and dynamics in diverse ways.3 These ligands can be broadly divided into 
two categories: those that inhibit the formation of the mitotic spindle, e.g. colchicine (1, Figure 1) and 
the vinca alkaloids, and those that inhibit the disassembly of the mitotic spindle once it has formed, e.g. 
paclitaxel and epothilone.4 Tubulin-binding compounds, such as paclitaxel and vinblastine, are in 
widespread clinical use for various types of cancer.3 
The combretastatins are a group of tubulin-binding diaryl stilbenes isolated from the stem wood of the 
South African tree Combretum Caffrum.5 There is no written evidence of use of the plant for treating 
cancer amongst the indigenous people of Africa.6 A number of constituent stilbenes were found to 
inhibit the growth of colon cancer cells and were strong inhibitors of tubulin polymerisation.5 
Combretastatin A-4 (2a, Figure 1) and combretastatin A-1 (2b, Figure 1) exhibited potent anticancer 
activity against a panel of human cancer cell lines from diverse origins, including leukaemic, breast and 
multi-drug resistant cancers.4 Stilbenes 2a and 2b inhibit the formation of the mitotic spindle by binding 
to the colchicine-binding site of tubulin and were also shown to exhibit anti-vascular properties in vivo, 
probably by increasing tumor-vessel permeability.7, 8 However, 2a and 2b display poor water solubility 
rendering them unsuitable for clinical use and water-soluble prodrugs, including combretastatin A-4-
phosphate (2c, Figure 1), are in clinical trials, for example evaluation of 2c for advanced anaplastic 
thyroid cancer and in combination with chemotherapy for advanced solid tumours.9-11 2c displays 
excellent water solubility, good stability and cell growth inhibitory activity comparable to that of 2a.11  
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However, the biological activity of 2a is lost if isomerization to the inactive trans form occurs, for 
example during storage.12, 13 Many conformationally restricted analogues of 2a are known, in which the 
cis double bond is replaced by a heterocycle, thereby locking the two aryl rings in a cis-like 
configuration relative to each other. A diverse range of heterocycles as replacements for the double bond 
have been reported including benzoxepins,14 oxadiazolines,15 imidazoles,16 combretoxazolones,17 
combretocyclopentenones13 and thiophenes,18 and are the subject of many reviews.4, 12, 19 Previously, β-
lactam containing compounds were reported to have anticancer activity20, 21 and the β-lactam ring 
scaffold has been investigated as a template for analogues of 2a.22-24 We have recently reported a series 
of antiproliferative, tubulin-binding β-lactam compounds, where 3a, 3b and 3c (Figure 1) emerged as 
the most potent agents with activity comparable to 2a.24 A 3-phenyl ring substituent improved the 
potency of this series of β-lactam compounds compared to either 3-methyl or 3,3-dimethyl substitution 
or β-lactams unsubstituted at C-3. β-Lactam 3b was shown to induce rapid apoptosis in vitro in 
leukaemic HL-60 cells and also induced apoptosis in ex vivo samples from patients with chronic 
myeloid leukaemia, including those positive for the T315I mutation displaying resistance to imatinib 
mesylate and dasatinib.25 Due to the potency of the 3-phenyl substituted compounds 3a and 3b, a series 
of novel analogues with diverse carbocycles and heterocycles to replace the phenyl ring were developed 
and evaluated for their antiproliferative activity and tubulin effects. These novel compounds reported 
herein contain carbocyclic, heterocyclic or modified aryl substituents at position 3 of the β-lactam ring 
while the aryl rings A and B present in 2a are retained at positions 1 and 4 of the azetidinone scaffold. 
The rigid β-lactam ring structure facilitates a similar spatial arrangement between the two aryl rings at 
N-1 and C-4 as is observed for the cis configuration of 2a. 
Insert Figure 1 
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2. Results and Discussion 
2.1 Chemistry 
The synthetic routes for target β-lactam preparation are illustrated in Schemes 1 – 6. The compounds 
chosen for initial investigation all contained the 3,4,5-trimethoxyphenyl (mimicking ring A of 2a) as the 
β-lactam N-1 substituent, together with the 4-methoxyphenyl ring as the β-lactam C-4 substituent. Two 
routes for the β-lactam ring-forming reaction were employed. The Staudinger reaction requires 
appropriately substituted acetic acids or acid chlorides and imines26 (Scheme 3; Routes I, II and III), 
while the Reformatsky reaction requires an organozinc species (derived from an α-bromoester) and an 
imine (Scheme 6).27 In two cases, the desired acetic acid precursors for β-lactam preparation were not 
commercially available. To prepare selected 2-thienyl containing derivatives, the appropriately 
substituted 2-thienyl aldehydes were converted to the corresponding acetic acids through the use of 
tetraethyl dimethylaminomethylenediphosphonate (4, Scheme 1).28 It was previously reported that the 
most convenient and efficient method to produce this aminodiphosphonate reagent was the reaction of 
dimethylchloroformiminium chloride with 2.2 equivalents of triethyl phosphite.29 The in-situ generated 
iminium ion reacts with triethyl phosphite to generate 4 in high yields of up to 76% (Scheme 1). This 
reagent reacts with the aldehyde of interest to form an enamine phosphonate, which is hydrolysed with 
strong acid to produce the substituted acetic acids 5a and 5b (Scheme 1). 
Substituted acetic acids were required in the Staudinger reaction for the preparation of β-lactams in 
two procedures. Firstly, the acid chloride could be generated from the acid for use in a traditional 
Staudinger reaction. Alternatively, direct preparation of β-lactams from substituted acetic acids by the 
Staudinger route using an acid-activating agent is possible (see below). In the first option, generation of 
the acid chloride (6a, 6b) from the corresponding substituted acetic acid was achieved by chlorination 
with thionyl chloride. The chlorination reactions were monitored by IR until absorption was observed 
between ν 1780 cm-1 and ν 1815 cm-1, due to carbonyl stretching in the acid chloride. Acid chlorides 6a 
and 6b were synthesised in high yield and were immediately used in the following β-lactam forming 
reaction without further purification (Scheme 3). 
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The preparation of imine precursors 8a – 8f is achieved in high yield by condensation of the 
appropriately substituted aldehydes and anilines (Scheme 2).30 In the case of 3-hydroxy-4-
methoxybenzaldehyde, the hydroxyl group was first protected using the TBDMS silyl ether group and 
then used for the preparation of Schiff base 8b.31  
The preparation of target β-lactams 10 – 27 is illustrated in Scheme 3. β-Lactam synthesis was 
primarily carried out using the Staudinger reaction, which is a cycloaddition reaction between a ketene 
and an imine under basic conditions, where the ketene can be generated from an acid chloride.32 β-
Lactams 10 – 18 were prepared by this method (Scheme 3, route I). A modified procedure for 
preparation of the 3-thienyl compound 19 was employed, as the standard Staudinger reaction conditions 
were unsuccessful. β-Lactam 19 was obtained in 48% yield using milder conditions with overnight 
stirring at room temperature (Scheme 3, route II).33 The stereochemistry of products from the Staudinger 
reaction depends on numerous factors, including the reaction conditions, the order of addition of the 
reagents and the substituents present on both the imine and on the acid chloride.20, 32, 34 The trans 
products were isolated exclusively in all but one case, as evident from the representative 1H NMR 
spectrum of compound 13 where the H-3 and H-4 were identified at δ 4.47 ppm and δ 4.90 ppm 
respectively as a pair of coupled doublets, J3,4 = 2.5 Hz. The formation of the trans isomer is likely due 
to steric hindrance when two aryl rings present in the β-lactam structure at C-3 and C-4. The sole 
exception in this series of compounds was the 3-methyl-3-phenyl substituted β-lactam 11, which was 
obtained as a mixture of cis/trans isomers (ratio 1:1.13 cis:trans) and separated by crystallization from 
ethanol. The presence of structural isomers was confirmed by X-ray crystal structures of both isomers of 
11 (Figure 2). Both enantiomers of 11 can be seen in the crystal structure of the trans isomer (Figure 
2b).  The X-ray crystal structure of 3,3-diphenyl β-lactam 12 is illustrated in Figure 3.  
Insert Figures 2 and 3 
The β-lactam ring scaffold could also be generated directly from the appropriately substituted acetic 
acid and imine precursors using an acid-activating agent in a one-step reaction, without generation and 
isolation of the acid chloride (Scheme 3, route III). Many acid-activating agents are known in literature, 
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e.g. Mukaiyama’s reagent, p-toluene-sulfonyl chloride and various phosphorous derived reagents.32 
Triphosgene has been reported for the synthesis of β-lactams and was employed as an acid-activating 
agent in synthesis of compounds 20 - 27.35, 36  
The phenolic products 28 and 29 were obtained on treatment of the silyl ethers 14 and 27 respectively 
with tetrabutylammonium fluoride at 0 ˚C (Scheme 4).31 Separation of the silylated β-lactams 14 and 27 
from the silylated imine in the final reaction mixture was difficult and hence removal of the silyl 
protecting group was carried out before subsequent purification. Reduction of the nitro group in 
compound 19 to the corresponding amine 30 was achieved by treatment with zinc dust and glacial acetic 
acid (Scheme 5).37   
Preliminary biochemical assessments of β-lactams 10 – 30 in MCF-7 human breast cancer cells 
revealed potent antiproliferative activity for thiophene containing compounds 13, 24, 28, 29 and 30 
(Table 2). On the basis of these results, further sulfur-containing β-lactam analogues were prepared. 3-
Unsubstituted β-lactam 9 was used as a precursor for a variety of substitution reactions at C-3. 
Compound 9 was obtained by Reformatsky reaction of imine 8a with ethylbromoacetate and zinc using 
microwave technology and TMCS as the zinc-activating agent as we have previously reported.24, 27 
Deprotonation of 9 with LDA at -78 °C followed by reaction with aldehydes32, 38 was successful for the 
preparation of secondary alcoholic derivatives 31 – 34 (Scheme 6). Further treatment of compounds 32 
and 33 by oxidation with pyridinium chlorochromate39 yielded ketone analogues 35 and 36 (Scheme 7). 
Transformation of alcoholic derivatives 32 and 34 by dehydration with tosyl chloride in pyridine38 
delivered corresponding vinylogous analogues 37 and 38 (Scheme 8). Although formation of E/Z 
isomers at the 3-position double bond is possible for 37 and 38, only one isomer was obtained in each 
case, possibly due to steric hindrance between the thiophene ring and aryl substituents at positions 3 and 
4 of the azetidinone ring. The  products 37 and 38 were assigned the Z configuration, by comparison of 
the signal for H-α in the 1H NMR spectrum (δ 6.45 ppm and δ 6.38 ppm for compounds 37 and 38 
respectively) with reported values for Hα in related E and Z 3-methylenesubstituted azetidin-2-ones.21 
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All β-lactam compounds 10 – 27 were obtained as enantiomeric mixtures and separation by chiral 
liquid chromatography was demonstrated for selected compounds 13 and 33, indicating a 1:1 mixture of 
the two enantiomers for both compounds (Figure 10, Supplementary Information). We have previously 
demonstrated stability of 3-phenyl β-lactams over the pH range 4 – 9.24 Preliminary stability studies of 
3-(2-thienyl) β-lactams with aryl, naphthyl and thienyl substituents at C-4 (compounds 13, 16, 17 and 
18) were carried out in acidic, neutral and basic pH conditions. The half-lives for these compounds were 
determined to be greater than 24 hours at pH values of 4, 7.4 and 9, with the compounds being least 
stable at pH 4 for all four analogues assessed. 
2.2 Biological Results and Discussion 
2.2.1 Antiproliferative effects 
The series of β-lactam analogues of 2a were initially evaluated for their antiproliferative activity in 
human MCF-7 breast cancer cells using the MTT cell viability assay.40 The previously reported lead 
compound, 3a, showed potent activity in this cancer cell line with an IC50 of 0.034 μM and further 
investigation established 3a and 3b as potential lead development candidates for the treatment of 
leukaemia.24, 25 To establish a more detailed SAR and further examine the effects of 3-substitution on 
antiproliferative activity, the phenyl ring at the 3-position of 3a was replaced with a wide variety of 
carbocyclic and heterocyclic substituents, while retaining the N-1, C-4 substituents of 3a (Table 1).  
The most potent β-lactams in MCF-7 cells were those with 3-(2-thienyl) (13) and 3-(3-thienyl) (24) 
substituents with IC50 values of 64 nM and 60 nM respectively. Replacement of the sulfur atom of 24 
with oxygen (furan analogue 23) led to a two-fold decrease in activity. Introduction of multiple and/or 
larger substituents at this position led to substantial decrease in activity compared to substitution with a 
phenyl ring, for example diphenyl 12 (IC50 of 43.17 μM), 1-naphthyl 20 (11.32 μM), 2-naphthyl 21 
(2.47 μM) and methyl indole 22 (6.59 μM). The bulky benzothiophene analogue 26 has a much greater 
IC50 value of 0.85 μM than the corresponding thiophene derivative 13 (IC50 value of 0.064 μM). This is 
in line with previous observations that poly-substitution of the C-3 phenyl ring led to decreased 
activity.24 A cyclohexane ring at position 3 of the β-lactam (10) showed decreased activity of over 100-
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fold compared to the 3-phenyl substituted compound 3a. Cyclohexane-substituted 10 has a higher cLogP 
value of 4.87 compared to 3.88 for 3a, indicating a marked increase in hydrophobicity. It is possible that 
this property contributes to its relative lack of antiproliferative activity. Disubstitution at the 3-position 
yielded the two compounds with the least antiproliferative activity in MCF-7 cells, 3-methyl-3-phenyl 
substituted 11 (IC50 of 43.45 μM; evaluated as a mixture of cis/trans isomers) and 3,3-diphenyl 
substituted 12 (IC50 of 43.17 μM). From these results, it can be deduced that substituents larger than a 
phenyl ring at the 3-position are detrimental to the antiproliferative activity of this series of compounds.  
Compounds 28 (IC50 = 7 nM) and 29 (IC50 = 10 nM) with additional hydroxyl groups at the 3-position 
of the 4-phenyl ring, analogous to 2a, displayed increased potency in MCF-7 cells over their respective 
parent compounds, 13 and 24, of 9-fold and 10-fold respectively. A dose response graph for 13, 29 and 
2a is shown in Figure 4. β-Lactam 30, in which the phenolic moiety of 28 is replaced with an amino 
substituent, was marginally more potent than 13 but less active than 28 (IC50 values of 42 nM, 64 nM 
and 7 nM respectively). Both 28 and 30 offer the possibility of further modification to form ester or 
amide prodrugs via their phenolic and amino groups. 
Insert Figure 4 
The effect of introduction of a carbon spacing atom between the thiophene ring and C-3 of the β-
lactam ring was investigated (compounds 14, 32 – 37). Secondary alcohols 32 and 33 and ketone 
derivatives 35 and 36 (IC50 values = 1.17 μM, 0.99 μM, 0.95 μM and 0.47 μM respectively) were over 
16-fold less potent than 13 and 24. Methylene 14 and alkene 37 have IC50 values of 1.64 μM and 4.05 
μM respectively, confirming that extension of the distance between the thiophene and β-lactam ring has 
a detrimental effect on the potency of this series.  
Analogues of 2a with a thiophene ring at the 3-position and naphthyl substituents at the 4-position (16 
and 17) in place of the 3-hydroxy-4-methoxyphenyl moiety were assessed for antiproliferative activity as 
the naphthyl moiety has been previously shown to be a good replacement for the B-ring of 2a.37 
However both 4-(2-naphthyl) β-lactam 16 and 4-(1-naphthyl) β-lactam 17 displayed decreased IC50 
values of 0.12 μM and 0.62 μM compared to 0.007 μM for 28. Replacement of the 4-position 
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substituted phenyl ring with a thiophene ring (18) led to decreased activity (IC50 value = 0.91 μM) 
indicating that, while a C-3 thiophene ring is advantageous for activity, such a substitution is not 
tolerated at C-4. 
The most active analogues in the MCF-7 antiproliferative studies (13, 28, 29 and 30) were 
subsequently evaluated against human MDA-MB-231 breast cancer cells and exhibited submicromolar 
IC50 values. Of the four compounds tested, 3-(3-thienyl) β-lactam 29 was the most potent (IC50 = 49 
nM) and showed improved activity compared to the lead compound 3a (IC50 = 78 nM) (Table 3).  
2.2.2 Further biochemical assessment: NCI60 cell line screen, cytotoxicity and tubulin 
polymerisation 
   Compounds 13, 28 and 30 were chosen for specific analysis and further development (screening in the 
National Cancer Institute (NCI) 60-cell line panel, determination of cytotoxicity, tubulin binding and 
molecular modelling) based on the analysis of their drug-like properties from a Tier-1 profiling screen 
(based on experimentally determined solubility and chemical stability together with together with 
predictions of permeability, metabolic stability, Pgp substrate status, blood-brain barrier partition, 
plasma protein binding and human intestinal absorption properties which indicated the suitability of 
these compounds for further development). These compounds satisfy Lipinski’s ‘rule of five’ for drug-
like properties e.g. molecular weights of 13, 28 and 30 are less than 500, the number of oxygen/nitrogen 
atoms is less than 10, the number of hydrogen bond donors is less than 5 and the cLogP values are 2.78, 
1.88 and 1.95 respectively (<5), implying that they are moderate lipophilic-hydrophobic drugs and are 
suitable candidates for further investigation.  
  3-Thienyl β-lactam 13 was screened using the NCI60 panel of cell lines (Table 5, supplementary 
information)41 and exhibited IC50 values of less than 10 nM in 25 of the 56 cell lines, and IC50 values of 
less than 51 nM in 47 of the cell lines. The mean GI50 value for 13 across all cell lines is 27.54 nM [log 
GI50=(-7.56M)]. The anti-proliferative activity of 13 was particularly potent for all three leukaemic cell 
lines (<10 nM) and for CNS, melanoma and breast cell lines, indicating a wide-range of potential 
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therapeutic applications. The mean LC50 for 13 across the range of cell lines is >100 μM indicating 
minimal cytotoxicity. In addition, matrix COMPARE analysis42, 43 (measuring the correlation between 
two compounds with respect to their differential antiproliferative activity) demonstrated good 
correlation between 13, 3b and 2a (r=0.76 and 0.61 respectively). However, this algorithm does not 
distinguish between different tubulin-based mechanisms of action.44 The COMPARE algorithm was 
also used to compare the differential antiproliferative activities of 13 to compounds with known 
mechanisms of action in the NCI Standard Agent Database4 and showed correlations to vincristine, 
paclitaxel, maytansine and rhizoxin, all of which affect microtubule polymerization (Table 4). 
2.2.3 Evaluation of toxicity in normal murine mammary epithelial cells 
   Further toxicity measurements were carried out on 3-(2-thienyl) β-lactam 28, the most potent 
antiproliferative β-lactam in antiproliferative assessment with MCF-7 cells. Toxicity studies in healthy 
mouse mammary epithelial cells at two different cell concentrations were carried out (25,000 cells/mL 
and 50,000 cells/mL harvested from mid- to late- pregnant CD-1 mice and cultured as described 
previously45, 46). These results indicate a favorable toxicity profile for 28 in comparison to 2a. The IC50 
value for both compounds was greater than 10 μM indicating minimal toxicity for this compound 
(Figure 5) (Table 7 and Figure 12, Supplementary Information).  
Insert Figure 5 
2.2.4 Tubulin polymerization studies 
The effects of representative β-lactam CA-4 analogue (compound 28) which demonstrated potent 
antiproliferative effects in vitro was assessed on the assembly of purified bovine tubulin. The ability of 
2a to effectively inhibit the assembly of tubulin was assessed as a positive control. Tubulin 
polymerisation was determined by measuring the increase in absorbance over time at 340 nm. The Vmax 
value offers the most sensitive indicator of tubulin/ligand interactions and hence fold-changes in Vmax 
values for polymerisation curves of the compound with reference to ethanol control were calculated. 
 13 
Tubulin polymerization studies on 28 showed a 3.2-fold reduction in the Vmax at 10 μM compared to a 
6-fold reduction for 2a tested as a control. The IC50 value for 28 for the inhibition of Vmax was 
calculated to be 1.37 ± 0.85 μM, while an IC50 value of 6.25 ± 2.53 μM was obtained for the effect in 
overall polymer mass (calculated from area under the polymerization curve) (Figure 6). This confirms 
that the molecular target of these antiproliferative β-lactams is tubulin. 
Insert Figure 6 
2.3 Structural Studies, Molecular Modeling and Rationalization of Biochemical Activity 
   Based on the 3D structural similarity between the ligands 1, 2a and the β-lactam analogues reported in 
this study, we propose that the binding site for these compounds is most likely to be the colchicine site, 
as it has been demonstrated that 2a and many reported examples of the structurally related 
conformationally constrained 2a analogues bind at the colchicine site.47-49 The colchicine-binding site in 
tubulin is mainly buried in the β-subunit of tubulin, whilst maintaining some limited interactions with 
the α-subunit. The H7 and H8 α-helices, the T7 loop and the S8 and S9 β-strands contribute to the 
binding site and interact with the colchicine-site ligand.50 Two of the most important residues for 
colchicine-binding are Val318 and Cys241. Val318 tubulin variants have reduced sensitivity to 1, and 1 
substituted with more reactive groups instead of the methoxys can be crosslinked with Cys241.51, 52 The 
Thr179 residue has also been highlighted as being important, though not critical, for binding.53 
Previously reported β-lactams 3a and 3b both show interactions with Val318 and Cys241, while 3b has 
an additional hydrogen-bonding interaction with Thr179.24  
The antiproliferative assessment of the β-lactam compounds 10 – 38 (Table 2) established a clear 
trend, where 2- and 3-thiophene substituents at C-3 proved extremely potent (e.g. compounds 13, 28, 29 
and 30). In contrast, bulkier substituents at the 3-position of the azetidinone ring (e.g. 3,3-diphenyl 
substituted analogue 12) led to a substantial decrease in activity, even though the required substitution 
pattern of rings A and B were preserved. To rationalize this observation, molecular structures of 
compounds 11 and 12, determined by single-crystal X-Ray crystallography, were examined (Figures 2 
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and 3). The structures revealed a conformation for the azetidinones 11 and 12 in which the two aromatic 
rings located at N-1 and C-4 are not coplanar. The observed dihedral angle between Ring A and Ring B 
in the X-ray crystal structures of these analogues is -61.7 ° for compound 12 (Figure 3). For compound 
11, a dihedral angle of 73.4 ° is observed for the cis isomer while values of 62.7 ° and -66.1 ° are 
calculated for the two enantiomers of the trans isomer (Figure 2). These values are very different to the 
dihedral angle previously observed for 3a of 46.9 °,24 and are also higher than the values for 1 (55 °)51 
and 2a (53 °)54. It is possible that this difference in orientation between the two rings is one of the 
factors leading to the decreased antiproliferative activity observed for 11 and 12. When these 
compounds 11 and 12 are docked computationally in the colchicine-binding site of tubulin, the reason 
for the decreased biochemical activity in vitro becomes apparent. The docked conformations of both 3a 
and 12 and of 1 and 12 (Figure 7) reveal that 12 is predicted to be orientated differently to both 3a and 1 
within the binding site. The N-1 trimethoxyphenyl rings of 3a and 12 adopt similar positions in the 
binding site but the C-4 4-methoxyphenyl ring lies in a different plane, projecting backwards for 1 and 
3a, but forward for 12. The 3,3-diphenyl rings of analogue 12 occupy the same part of the binding site as 
the 4-(4-methoxyphenyl) ring of 3a, indicating that this part of the colchicine-binding site of tubulin can 
accommodate a larger volume and explains the relative switch in orientation for 12 compared to 1 and 
3a. This may account for the loss in antiproliferative activity seen with 12 and any other related 
analogues with a bulky substitution pattern at this position (e.g. compounds 11 20, 21 and 22), as the 
potential for forming a binding interaction with Thr179 is lost and microtubule dynamics may not be as 
dramatically affected. However, interactions between the N-1 trimethoxyphenyl ring of 12 and both 
Val318 and Cys241 are maintained, accounting for the residual antiproliferative activity of this 
compound. 
Insert Figure 7 
In contrast to 3,3-diphenyl β-lactam 12, virtual molecular docking of the most potent β-lactam from 
this series, 3-(2-thienyl) β-lactam 28, predicts a docked conformation similar to that previously predicted 
for 3b (Figure 8, also figure 11 in supplementary information).24 The dihedral angle between the N-1 
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and C-4 phenyl rings of 28, calculated from the energy minimized structure rather than a crystal 
structure, is 61.8°. The predicted 2D interactions of the ligand with the protein are shown in figure 9.55 
Residues Cys241 and Val318 interact with the trimethoxyphenyl ring of 28. Hydrogen bonding of the 
phenolic group of ring B to Thr179 and Lys352 contributes to the strong tubulin binding of this 
compound observed in vitro and is suggested to account for the increased antiproliferative activity seen 
with the phenolic compounds 28 and 29. Further hydrophobic interactions between the 3-(2-thienyl) ring 
and the colchicine site residues (Figure 9) reinforce the binding to the protein, for example with Val181, 
Leu248 and Ala250. These interactions, in contrast to those of β-lactam 12, may stabilize the binding of 
28 and provide a rational basis for the potent antiproliferativea nd tubulin-binding activity displayed by 
these compounds. 
Insert Figures 8 and 9 
Summary and conclusion 
Building on previous work where the β-lactam ring scaffold was utilized to replace the isomerisable 
double-bond of 2a, further investigations to determine a comprehensive SAR of antiproliferative β-
lactams has led to the new discovery of novel analogues with significant antiproliferative and tubulin-
binding activity. A trend for small ring heterocyclic systems at the 3-position ring leading to increased 
potency was determined, with larger ring systems such as naphthyl, indole and benzothiophene leading 
to significantly less potent anti-proliferative activities. 3-(2-Thienyl) and 3-(3-thienyl) derivatives 28 and 
29 displayed the most potent antiproliferative activity in MCF-7 and MDA-MB-231 breast cancer cell 
lines with low nanomolar antiproliferative IC50 values, and 28 was shown to be minimally toxic to 
normal murine epithelial cells. The molecular target of β-lactam 28 was confirmed to be tubulin, and 
this compound displayed an IC50 value of 1.37 μM for inhibition of tubulin polymerization. The 2-
thienyl and 3-thienyl containing compounds reported herein will be evaluated in further in vitro and in 
vivo studies to develop their potential vascular targeting and antiangiogenic applications. 
3. Experimental Section 
3.1 Chemistry: Experimental Methods 
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All reagents were commercially available and were used without further purification unless otherwise 
indicated.  Tetrahydrofuran (THF) was distilled immediately prior to use from Na/Benzophenone under 
a slight positive pressure of nitrogen, toluene was dried by distillation from sodium and stored on 
activated molecular sieves (4 Å) and dichloromethane was dried by distillation from calcium hydride 
prior to use.  IR spectra were recorded as thin films on NaCl plates or as KBr discs on a Perkin-Elmer 
Paragon 100 FT-IR spectrometer. 1H and 13C NMR spectra were obtained on a Bruker Avance DPX 400 
instrument at 20 oC, 400.13 MHz for 1H spectra, 100.61 MHz for 13C spectra, in CDCl3 (internal 
standard tetramethylsilane) by Dr. John O’Brien and Dr. Manuel Ruether in the School of Chemistry, 
Trinity College Dublin.  Low resolution mass spectra were run on a Hewlett-Packard 5973 MSD GC–
MS system in an electron impact mode, while high resolution accurate mass determinations for all final 
target compounds were obtained on a Micromass Time of Flight mass spectrometer (TOF) equipped 
with electrospray ionization (ES) interface operated in the positive ion mode at the High Resolution 
Mass Spectrometry Laboratory by Dr. Martin Feeney in the School of Chemistry, Trinity College 
Dublin. Elemental analysis was carried out in the microanalytical laboratory, University College Dublin, 
Belfield, Dublin 4. Thin layer chromatography was performed using Merck Silica gel 60 TLC 
aluminium sheets with fluorescent indicator visualizing with UV light at 254 nm. Flash chromatography 
was carried out using standard silica gel 60 (230-400 mesh) obtained from Merck. All products isolated 
were homogenous on TLC. Analytical high-performance liquid chromatography (HPLC) to determine 
the purity of the final compounds was performed using a Waters 2487 Dual Wavelength Absorbance 
detector, a Waters 1525 binary HPLC pump, a Waters In-Line Degasser AF and a Waters 717plus 
Autosampler. The column used was a Varian Pursuit XRs C18 reverse phase 150 x 4.6mm 
chromatography column. Samples were detected using a wavelength of 254 nm. All samples were 
analyzed using acetonitrile (70%): water (30%) over 10 min and a flow rate of 1 mL/min. Unless 
otherwise indicated, the purity of the final products was ≥ 95% (see table 6, supplementary information). 
Chiral liquid chromatography was carried out on selected compounds using a Chiral-AGPTM 150x4.0 
mm column supplied by ChromTech Ltd. (now supplied by Chiral Technologies Europe) with a Chiral- 
 17 
AGPTM guard column and the same Waters hardware as used above for purity testing. Gradient elution 
was used beginning with 10% of organic phase and finishing with 90% of organic phase over a period of 
20 minutes. The organic mobile phase was 2-propanol and the aqueous phase was a sodium phosphate 
buffer. The sodium phosphate buffer, consisting of 10 mM sodium dihydrogen orthophosphate dihydrate 
(NaH2PO4) in HPLC-grade water, was made up to pH 7.0 using sodium hydroxide. The flow rate was 
0.5 mL/min and detection was carried out at 225 nm.  
3.1.1 3-(tert-Butyldimethylsilanyloxy)-4-methoxybenzaldehyde. To a solution of 3-hydroxy-4-
methoxybenzaldehyde (0.02 mol) and dimethyl-tert-butylchlorosilane (0.024 mol) in dry CH2Cl2 (60 
mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.032 mol). The resulting mixture was 
stirred at room temperature under a nitrogen atmosphere until complete on thin layer chromotagraphy. 
The solution was then diluted with CH2Cl2 (80 mL) and washed successively with water (60 mL), 0.1M 
HCl (60 mL) and saturated aqueous NaHCO3 (60 mL). The organic layer was removed and dried by 
filtration through anhydrous sodium sulphate, Na2SO4. 3-(tert-Butyldimethylsilanyloxy)-4-
methoxybenzaldehyde was isolated as a brown oil (yield 93.8%)56; 1H NMR (400 MHz, CDCl3) δ 0.19 
(s, 6H, -SiCH3), 1.02 (s, 9H, -CH3), 3.91 (s, 3H, OCH3), 6.97 (d, 1H, J=8.52 Hz, ArH), 7.39 (s, 1H, 
ArH), 7.48 – 7.50 (m, 1H, ArH), 9.83 (s, 1H, -CHO); 13C NMR (100 MHz, CDCl3) δ 18.43 (-SiCH3), 
25.65 (-CH3), 55.58 (OCH3), 111.19, 120.05, 126.39, 130.17, 145.57, 156.65 (ArC), 191.01 (CHO); 
HRMS (M++H):  C14H22O3S requires 266.1338; found: 266.1349 
3.1.2 Tetraethyl dimethylaminomethylenediphosphonate (4):  To a chilled solution of 
dimethylformamide (97.9 mmol) in diethyl ether (150 mL) was added dropwise with stirring a solution 
of oxalyl chloride (97.9 mmol) in diethyl ether (20 mL). Following addition, the mixture was allowed to 
warm to room temperature and stirred for 1 hour. Triethyl phosphite (215 mmol) was then added 
dropwise with stirring. After one hour the mixture was concentrated under reduced pressure. The 
product was obtained as a yellow oil in 75.5% yield.28; δ 0.92 (m, 12H, 4xCH3), 2.19 (s, 6H, 2xCH3), 
2.90 (t, 1H, 4xCH), 3.68 – 3.80 (m, 8H, CH2); HRMS (M++Na): C11H27NNaO6P2 requires 354.1211; 
found: 354.1218  
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3.1.3 General method for preparation of enamine phosphonate 
To a suspension of NaH (33 mmol) in dry toluene (20 mL) was added dropwise with stirring a 
solution of 4 (16.7 mmol) in dry toluene (20 mL). After one hour, a solution of the appropriate aldehyde 
(16.7 mmol) in dry toluene (20 mL) was added. The mixture was stirred at 50 ˚C for one hour and then 
concentrated. The residue was partitioned between ethyl acetate and water and the aqueous layer was 
extracted with ethyl acetate three times. The residue was purified by column chromatography (hexane: 
ethyl acetate gradient) to afford the clean product. 
3.1.3.1 (2-Benzo[b]thiophen-2-yl-1-dimethylaminovinyl)phosphonic acid diethyl ester was 
obtained by reaction of benzo[b]thiophene-2-carbaldehyde with tetraethyl 
dimethylaminomethylenediphosphonate (4). The product was obtained as a dark orange oil (56.7% 
yield).28, 29 1H NMR (400 MHz, CDCl3) δ 1.36 (t, 6H, 2xCH3), 2.69 (s, 6H, 2xCH3), 4.12 – 4.22 (m, 4H, 
2xCH2), 7.31 – 7.40 (m, 3H, ArH), 7.73 – 7.78 (m, 2H, ArH) ; HRMS (M++Na): C16H22NNaO3PS 
requires 362.0956; found: 362.0946  
3.1.3.2 [1-Dimethylamino-2-(5-methylthiophen-2-yl)vinyl]phosphonic acid diethyl ester was 
obtained by reaction of 5-methyl-thiophene-2-carbaldehyde with tetraethyl 
dimethylaminomethylenediphosphonate (4). The product was obtained as a dark orange oil (22.5% 
yield); 1H NMR (400 MHz, CDCl3) δ 1.32 (t, 6H, 2xCH3), 2.45 (s, 3H, CH3), 2.60 (s, 6H, 2xCH3), 4.06 
– 4.13 (m, 4H, 2xCH2), 6.63 (s, 1H, CH), 6.98 (d, 1H, J=3.52, ArH), 7.18 (d, 1H, J=12.04, ArH); 
HRMS (M++Na): C13H22NNaO3PS requires 326.0956; found: 326.0972 
3.1.4 General procedure for hydrolysis of enamine phosphonates: The appropriate enamine 
phosphonate was refluxed in 10M HCl (50 mL) for 30 minutes. The mixture was poured onto ice water 
(200 mL) and extracted with ethyl acetate (twice).  The combined organic extracts were dried over 
anhydrous Na2SO4 and concentrated to give the desired product.  
3.1.4.1 Benzo[b]thiophen-2-yl-acetic acid (5a) was obtained from (2-benzo[b]thiophen-2-yl-1-
dimethylamino-vinyl)phosphonic acid diethyl ester as a light brown powder (61.2% yield); Mp: 130°C 
(lit. 140 - 142°C29); IR (KBr disk) νmax: 1715.55 cm-1 (-C=O); 1H NMR (400 MHz, CDCl3) δ 3.99 (s, 
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2H, CH2), 7.24 – 7.37 (m, 3H, ArH), 7.74 – 7.76 (m, 1H, ArH), 7.81 – 7.83 (m, 1H, ArH); 13C NMR 
(100 MHz, CDCl3) δ 35.39 (CH2), 122.18, 123.36, 124.06, 124.19, 124.39, 135.03, 139.60, 140.03 
(ArC), 175.87 (C=O) 
3.1.4.2 (5-Methylthiophen-2-yl)acetic acid (5b) was obtained as a brown oil from [1-dimethylamino-
2-(5-methylthiophen-2-yl)-vinyl]-phosphonic acid diethyl ester (1% yield) and was used immediately in 
the subsequent reaction without further purification29; IR (KBr disk) νmax: 1705.90 cm-1 (-C=O); 1H 
NMR (400 MHz, CDCl3) δ 2.49 (s, 3H, CH3), 3.83 (s, 2H, CH2), 6.65 (d, 1H, J=2.52, ArH), 6.77 (d, 1H, 
J=2.52, ArH); 13C NMR (100 MHz, CDCl3) δ 15.29 (CH3), 35.25 (CH2), 124.99, 127.19, 131.63, 
139.95, 177.04 (C=O) 
3.1.5 General method for chlorination of acetic acid derivatives: The appropriate acetic acid (10 
mmol) was brought to reflux with thionyl chloride (12 mmol) in chloroform (30 mL). The reaction was 
monitored by I.R. until absorption appeared between 1780cm-1 and 1815cm-1. The solvent was 
evaporated under reduced pressure. 
3.1.5.1 2-Phenylpropionyl chloride (6a)57 was prepared from phenylpropionic acid in 92.2% yield as 
a pale yellow oil and was used immediately in the subsequent reaction without further purification; IR 
(KBr) νmax: 1784.17 cm-1 (-C=O, acid chloride). 
3.1.5.2 3-Thiophen-2-yl-propionyl chloride (6b)58 was prepared from 3-thiophen-2-yl-propionic 
acid (10 mmol) and was used immediately in the subsequent reaction without further purification (pale 
yellow oil, 90.9% yield); IR (KBr) νmax: 1782.84 cm-1 (-C=O, acid chloride) 
3.1.6 General method for imine formation 
The appropriate amine (10 mmol) was heated at reflux with the appropriate aldehyde (10 mmol) in 
ethanol (50 mL) for 3 hours. The reaction mixture was reduced in vacuo and the resulting solution was 
left to stand until solid product crystallised. The resulting imine was recrystallised from ethanol. 
3.1.6.1 N-(4-Methoxybenzylidene)-3,4,5-trimethoxybenzenamine (8a) was synthesised by reacting 
3,4,5-trimethoxybenzenamine with 4-methoxybenzaldehyde. The product was obtained as pale yellow 
crystals (yield 87%); mp: 120°C24; IR (KBr disk) νmax: 1604.66 cm-1 (C=N); 1H NMR (400 MHz, 
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CDCl3)  δ 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.90 (s, 6H, 2x OCH3)  6.47 (s, 2H, ArH)  6.98 (d, 
2H, J=9.2 Hz, ArH)  7.84 (d, 2H, J=9.2 Hz, ArH)  8.40 (s, 1H, -CH=N); 13C NMR (100 MHz, CDCl3)  δ 
55.35 (OCH3), 56.00 (OCH3), 60.94 (OCH3), 98.00, 114.13, 128.97, 130.39, 135.97, 148.22, 153.45, 
159.03(ArC), 162.20 (CH=N); Elemental analysis: Found: C, 67.73; H, 6.35; N, 4.63; C17H19NO4 
requires C, 67.76; H, 6.36; N, 4.65%. 
 3.1.6.2 [3-(tert-Butyldimethylsilanyloxy)-4-methoxybenzylidene](3,4,5-trimethoxyphenyl)amine 
(8b) was synthesised by reaction of 3-(tert-butyldimethylsilanyloxy)-4-methoxybenzaldehyde with 
3,4,5-trimethoxybenzenamine. The product was obtained as a yellow solid. Yield 64%, mp: 105°C24; IR 
(KBr disk) νmax 1619.77 cm-1, 1579.73 cm-1 (C=N); 1H NMR (400 MHz, CDCl3) δ δ 0.20 (s, 6H, 
2xCH3), 1.03 (s, 9H, C(CH3) 3), 3.87 – 3.91 (m, 12H, 4xOCH3), 6.48 (s, 2H, ArH), 6.93 (d, 2H, J=8.04 
Hz, ArH), 7.43 – 7.47 (m, 1H, ArH), 8.35 (s, 1H, CH=N); 13C NMR (100 MHz, CDCl3) δ –5.04(CH3-
Si-CH3), 18.03(CH3-C-CH3), 25.27(C(CH3)3), 54.98(OCH3), 55.63(OCH3), 97.62, 110.94, 119.71, 
123.48, 128.95, 135.53, 144.87, 147.94, 153.05, 153.59 (ArC), 158.84(C=N); HRMS (M++H): 
C23H34NO5Si requires 432.2206; found: 432.2213  
3.1.6.3 (4-Methoxy-3-nitrobenzylidene)(3,4,5-trimethoxyphenyl)amine (8c) was synthesised by 
reaction of 3,4,5-trimethoxyphenylamine and 4-methoxy-3-nitrobenzaldehyde. The product was 
obtained as a yellow powder (yield 88%); mp: 162 – 163°C24; IR (KBr disk) νmax 1616.90cm-1, 
1580.79cm-1(C=N); 1H NMR (400 MHz, CDCl3) δ 3.89 (s, 3H, OCH3), 3.93 (s, 6H, 2x OCH3), 4.06 (s, 
3H, OCH3), 6.52 (s, 2H, ArH),  7.21 (d, 1H, J=8.52 Hz, ArH),  8.13 (dd, 1H, J=8.52 Hz, J=2.48 Hz, 
ArH),  7.39 (d, 1H, J=2.48 Hz, ArH),  8.45 (s, 1H, (C=N); 13C NMR (100 MHz, CDCl3) δ 55.70 
(OCH3), 56.40 (OCH3), 60.59 (OCH3), 97.75, 113.20, 125.59, 128.52, 133.29, 146.59, 153.19, 154.41 
(ArC), 155.66 (C=N). Elemental analysis: Found: C, 58.91; H, 5.25; N, 7.95; C17H18N2O6 requires C, 
58.96; H, 5.24; N, 8.09%. 
3.1.6.4 3,4,5-Trimethoxy-N-(naphthalen-2-ylmethylene)aniline (8d) was synthesised using 3,4,5-
trimethoxyphenylamine and 2-naphthaldehyde as a yellow solid (78% yield); mp:: 132-136 °C; IR (KBr 
disk) νmax: 1626.22 and 1581.26 cm-1 (C=N); 1H NMR (400 MHz, CDCl3): δ 3.91 (s, 3H, OCH3), 3.95 
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(s, 6H, 2xOCH3), 6.29 (s, 2H, ArH), 7.58 (m, 2H, ArH), 7.94 – 7.96 (m, 3H, ArH), 8.84 (m, 2H, ArH),  
8.67 (s, 1H, HC_N); Elemental analysis: Found: C, 74.68; H: 6.02; N: 4.31; C20H19NO9 requires C, 
74.65, H, 5.98, N, 4.26 
3.1.6.5 3,4,5-Trimethoxy-N-(naphthalen-1-ylmethylene)aniline (8e) was synthesised using 3,4,5-
trimethoxyphenylamine and 2-naphthaldehyde as a yellow solid (77% yield); mp: 108-116 °C; IR (KBr 
disk) νmax: 1625.74, 1610.62 and 1583.40 cm-1 (C=N); 1H-NMR (400 MHz, CDCl3): δ 3.92 (s, 3H, 
OCH3), 3.96 (s, 6H, 2xOCH3), 6.61 (s, 2H, ArH), 7.59 – 7.67 (m, 3H, ArH), 7.96 (d, 1H, J=8.52 Hz, 
ArH), 8.02 (d, 1H, J=8 Hz, ArH), 8.12 (m, 1H, ArH), 9.05 (d, 1H, J=8.52 Hz, ArH), 9.15 (s, 1H, HC_N); 
Elemental analysis: Found: C, 74.67, H, 5.97, N, 4.30; C20H19NO9 requires C, 74.65, H, 5.98, N, 4.26 
3.1.6.6 3,4,5-Trimethoxy-N-(thiophen-2-ylmethylene)aniline (8f) was synthesised from 3,4,5-
trimethoxyphenylamine and thiophene-2-carbaldehyde as a yellow solid (81% yield); mp: 92-98 °C; IR 
(KBr disk) νmax: 1617.78 and 1584.53 cm-1  (C=N); 1H-NMR (400 MHz, CDCl3): δ 3.88 (s, 3H, OCH3), 
3.92 (s, 6H, 2xOCH3), 6.52 (s, 2H, ArH), 7.16 – 7.18 (m, 1H, ArH), 7.52 – 7.55 (m, 2H, ArH), 8.61 (s, 
1H, HC=N); Elemental analysis: Found: C, 60.62; H, 5.44; N, 5.01;  C14H15NO3S requires C, 60.63; H, 
5.45; N=5.05 
3.1.7 4-(4-Methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (9): Zinc powder (0.927g, 15 
mmol) was activated using trimethylchlorosilane (0.65 mL, 5 mmol) in anhydrous benzene (5 mL), by 
heating for 15 minutes at 40 °C and subsequently for 2 minutes at 100 °C in a microwave. After cooling, 
N-(4-methoxybenzylidene)-3,4,5-trimethoxybenzenamine (8a) (10 mmol) and ethyl 2-bromoacetate (12 
mmol) were added to the reaction vessel and the mixture was placed in the microwave for 30 minutes at 
100°C. The reaction mixture was filtered through Celite to remove zinc, then diluted with CH2Cl2 (50 
mL). This solution was washed with saturated ammonium chloride solution (20 mL) and 25% 
ammonium hydroxide (20 mL), and then with dilute HCl (40 mL), followed by water (40 mL). 4-(4-
Methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (9) was obtained as green crystals (yield 
43%); mp: 70-71°C; IR (NaCl film) νmax: 1747.5 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3): δ 
2.85 (dd, 1H, J= 2.48 Hz, 12.56 Hz, H-3), 3.48 (dd, 1H, J=5.52 Hz, J=9.56 Hz, H-4), 3.65 (s, 6H, 
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2xOCH3), 3.70 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 4.88 (d, 1H, J= 2.76 Hz, H-4), 6.53 (s, 2H, ArH), 
6.86 (d, 2H, J=8.56 Hz, ArH), 7.26 (d, 2H, J=8.56 Hz, ArH);  13C NMR (100 MHz, CDCl3): δ 46.36 (C-
3), 53.56 (OCH3), 54.78 (OCH3), 55.23 (OCH3), 55.49 (OCH3), 60.36 (C-4), 93.92, 113.58, 126.83, 
129.48, 133.62, 133.68, 152.94, 159.29 (ArC), 164.14 (C=O); HRMS (M++Na): Found 366.1330; 
C19H21NO5Na requires 366.1317. 
3.1.8 General method I for β-lactam preparation: The appropriate imine (5 mmol) and 
triethylamine (15 mmol) were added to dry CH2Cl2 (50 mL) and the mixture was brought to reflux at 
60°C. Once refluxing, the appropriately substituted acid chloride (7.5 mmol) was injected dropwise 
through a rubber stopper. This mixture was refluxed for 3 hours. The mixture was washed firstly with 
distilled water (50 mL) (twice) and then with saturated aqueous sodium bicarbonate solution (50 mL). 
The organic layer was dried by filtration through anhydrous sodium sulfate. The organic layer containing 
the product was reduced in vacuo. The pure product was isolated by flash column chromatography over 
silica gel (hexane: ethyl acetate gradient). 
3.1.8.1 3-Cyclohexyl-4-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (10) was 
obtained from 2-cyclohexylacetyl chloride  and N-(4-methoxybenzylidene)-3,4,5-
trimethoxybenzenamine (8a)  as a white powder (15.0% yield); Mp: 144ºC; IR (NaCl film) νmax: 
1744.47cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 1.14 – 1.32 (m, 5H, CH2), 1.68 - 1.78 (m, 
3H, CH2), 1.82 – 1.90 (m, 2H, CH2), 2.05 – 2.09 (m, 1H, CH), 2.96 (m, 1H, H-3), 3.71 (s, 6H, 
2xOCH3), 3.77 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.69 (d, 1H, J=2.52 Hz, H-4), 6.54 (s, 2H, ArH), 
6.89 – 6.93 (m, 2H, ArH), 7.28 – 7.31 (m, 2H, ArH); 13C NMR (100 MHz, CDCl3) δ 25.77 (CH2), 25.92 
(CH2), 26.22 (CH2), 30.71 (CH2), 30.92 (CH2), 38.28 (CH), 55.31 (OCH3), 55.94 (OCH3), 58.93 (C-3), 
60.93 (OCH3), 66.11 (C-4), 94.45, 114.51, 127.23, 130.28, 134.05, 134.08, 153.42, 159.57 (ArC), 
167.47 (C=O); HRMS (M++Na): C25H31NO5Na requires 448.2100; found 448.2101 
3.1.8.2 4-(4-Methoxyphenyl)-3-methyl-3-phenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (11) was 
obtained from 2-phenylpropionyl chloride (6a) and N-(4-methoxybenzylidene)-3,4,5-
trimethoxybenzenamine (8a) as a white powder (29.4% yield); Mp: 183ºC; IR (NaCl film) νmax: 1737.24 
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cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) (cis isomer) δ 1.91 (s, 3H, CH3), 3.72 – 3.73 (m, 
9H, 3xOCH3), 3.79 (s, 3H, OCH3), 5.00 (s, 1H, H-4), 6.66 (d, 2H, J=7 Hz, ArH), 6.94 (d, 2H, J=8 Hz, 
ArH), 7.09 – 7.13 (m, 5H, ArH); 13C NMR (100 MHz, CDCl3) (cis isomer) δ 24.34 (CH3), 54.68 
(OCH3), 55.52 (OCH3), 60.50 (OCH3), 64.01 (C-3), 68.32 (C-4), 94.53, 113.23, 126.28, 126.81, 127.59, 
128.10, 133.60, 133.87, 137.32, 152.96, 158.84 (ArC), 168.80 (C=O); 1H NMR (400 MHz, CDCl3) 
(trans isomer) δ 1.91 (s, 3H, CH3), 3.73 (s, 6H, 2xOCH3), 3.80 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 5.19 
(s, 1H, H-4), 6.64 (d, 2H, J=7 Hz, ArH), 6.97 (d, 2H, J=8 Hz, ArH), 7.12 (m, 1H, ArH), 7.28 – 7.34 (m, 
3H, ArH), 7.40 – 7.44 (t, 2H, ArH), 7.55 – 7.56 (m, 2H, ArH); 13C NMR (100 MHz, CDCl3) (trans 
isomer) δ 19.20 (CH3), 54.86 (OCH3), 55.52 (OCH3), 55.58 (OCH3), 60.53 (OCH3), 62.13 (C-3), 66.56 
(C-4), 94.68, 113.23, 113.80, 125.43, 126.08, 126.81, 126.90, 127.59, 127.82, 128.10, 128.47, 133.24, 
141.43, 153.01, 159.13 (ArC), 168.77 (C=O); HRMS (M++H): C26H28NO5 requires 434.1967; found 
434.1953 
3.1.8.3 4-(4-Methoxyphenyl)-3,3-diphenyl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (12) was 
obtained 2,2-diphenylacetyl chloride and N-(4-methoxybenzylidene)-3,4,5-trimethoxybenzenamine (8a) 
as a white crystalline material (70.3% yield); Mp: 167ºC; IR (KBr disk) νmax: 1729.20 cm-1 (C=O, β-
lactam); 1H NMR (400 MHz, CDCl3) δ 3.72 – 3.74 (m, 9H, 3xOCH3), 3.78 (s, 3H, OCH3), 5.74 (s, 1H, 
H-4), 6.68 – 6.72 (t, 4H, ArH), 7.06 – 7.09 (m, 5H, ArH), 7.16 – 7.18 (m, 2H, ArH), 7.29 – 7.32 (t, 1H, 
ArH), 7.39 – 7.43 (m, 2H, ArH), 7.67 (d, 2H, J=7.52 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ 54.74 
(OCH3), 55.53 (OCH3), 58.06 (OCH3), 60.50 (OCH3), 66.94 (C-4), 71.53 (C-3), 94.70, 113.35, 126.33, 
126.38, 126.78, 127.00, 127.54, 127.91, 128.35, 128.44, 133.26, 134.02, 136.77, 140.44, 152.94, 159.00 
(ArC), 166.70 (C=O); HRMS (M++Na): C31H29NO5Na requires 518.1943; found 518.1962 
3.1.8.4 4-(4-Methoxyphenyl)-3-thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (13) was 
obtained from 2-(thiophen-2-yl)acetyl chloride and N-(4-methoxybenzylidene)-3,4,5-
trimethoxybenzenamine (8a) as a white powder (4.6% yield); Mp: 115ºC; IR (NaCl film) νmax: 
1756.78cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.72 (s, 6H, 2xOCH3), 3.77 (s, 3H, 
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OCH3), 3.82 (s, 3H, OCH3), 4.47 (d, 1H, J=2.5 Hz, H-3), 4.90 (d, 1H, J=2.5 Hz, H-4), 6.59 (s, 2H, 
ArH), 6.95 (d, 2H, J=8.56 Hz, ArH), 7.01 – 7.03 (t, 1H, ArH), 7.08 (d, 1H, J=3.48 Hz, ArH), 7.26 (d, 
1H, ArH, J=5 Hz), 7.36-7.38 (d, 2H, ArH, J=8.52 Hz); 13C NMR (100 MHz, CDCl3) δ 54.93 (OCH3), 
55.58 (OCH3), 59.78 (C-3), 60.52 (OCH3), 64.12 (C-4), 94.46, 113.86, 114.27, 124.43, 124.87, 125.29, 
126.82, 126.90, 128.29, 133.19, 134.11, 135.70, 148.98, 153.06, 159.60 (ArC), 163.98 (C=O); HRMS 
(M++Na): C23H23NO5NaS requires 448.1195; found 448.1186 
3.1.8.5 4-(3-((tert-Butyldimethylsilyl)oxy)-4-methoxyphenyl)-3-(thiophen-2-yl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (14) was obtained from 2-(thiophen-2-yl)acetyl chloride and [3-(tert-
butyldimethylsilanyloxy)-4-methoxybenzylidene](3,4,5-trimethoxyphenyl)amine (8b) as a brown oil and 
was desilylated to form 33 without further purification (crude yield: 4.3%). 
3.1.8.6 4-(4-Methoxyphenyl)-3-(thiophen-2-ylmethyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(15) was obtained from 3-thiophen-2-yl-propionyl chloride (6b) and N-(4-methoxybenzylidene)-3,4,5-
trimethoxybenzenamine (8a) and isolated as a yellow oil in 0.6% yield; IR (NaCl film) νmax: 1746.67 
cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.30 – 3.36 (m, 1H, CH2), 3.40 – 3.44 (m, 1H, 
CH2), 3.49 – 3.54 (m, 1H, H-3), 3.72 (s, 6H, 2xOCH3), 3.78 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.71 (d, 
1H, J=2.5 Hz, H-4), 6.54 (s, 2H, ArH), 6.86 – 6.89 (m, 3H, ArH), 6.94 – 6.97 (m, 1H, ArH), 7.16 – 7.19 
(m, 3H, ArH); 13C NMR (100 MHz, CDCl3) δ 28.32 (CH2), 54.84 (OCH3), 55.56 (OCH3), 60.25 (C-3), 
60.49 (C-4), 94.33, 113.99, 123.71, 125.32, 126.63, 126.85, 128.89, 133.37, 139.45, 153.01, 159.23 
(ArC), 165.95 (C=O); HRMS (M++Na): C24H25NO5NaS requires 462.1351; found 462.1333 
3.1.8.7 1-(3,4,5-Trimethoxyphenyl)-4-(naphthalen-2-yl)-3-(thiophen-2-yl)azetidin-2-one (16) was 
obtained from 2-(thiophen-2-yl)acetyl chloride and 3,4,5-trimethoxy-N-(naphthalen-2-
ylmethylene)aniline (8d) as a brown oil (9.1% yield); IR (KBr disk) νmax: 1754.84 cm-1 (C=O); 1H-NMR 
(400 MHz, CDCl3): δ 3.70 (s, 6H, 2xOCH3), 3.78 (s, 3H, OCH3), 4.59 (d, 1H, J=2.0 Hz, H-3), 5.15 (d, 
1H, J=2.0 Hz, H-4), 6.66 (s, 2H, ArH), 7.07 – 7.08 (m, 1H, ArH), 7.13 – 7.14 (m, 1H, ArH), 7.29 (s, 1H, 
ArH), 7.34 – 7.35 (m, 1H, ArH), 7.54 – 7.57 (m, 2H, ArH), 7.88 – 8.03 (m, 4H, ArH); 13C-NMR (400 
MHz, CDCl3): δ 55.59 (OCH3), 59.75 (OCH3), 60.51 (OCH3), 64.12 (C-3), 64.64 (C-4), 94.46, 114.27, 
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122.35, 125.02, 125.07, 125.47, 126.26, 126.41, 126.96, 127.46, 129.17, 132.89, 133.06, 133.25, 
133.94, 135.55, 153.13 (ArC), 163.88 (C=O); HRMS (M++Na): C23H23NO5NaS requires 468.1245; 
found 468.1227 
3.1.8.8 1-(3,4,5-Trimethoxyphenyl)-4-(naphthalen-1-yl)-3-(thiophen-2-yl)azetidin-2-one (17) was 
obtained from 2-(thiophen-2-yl)acetyl chloride and 3,4,5-trimethoxy-N-(naphthalen-1-
ylmethylene)aniline (8e) as a brown oil (15.2% yield); IR (KBr disk) νmax: 1755.27 cm-1 (C=O); 1H 
NMR (400 MHz, CDCl3): δ 3.71 (s, 6H, 2xOCH3), 3.83 (s, 3H, OCH3), 4.54 (d, 1H, J=2.5 Hz), 5.77 (d, 
1H, J=2.5 Hz), 6.69 (s, 2H, ArH), 7.07 (m, 1H, ArH), 7.14 (s, 1H, ArH), 7.38-7.40 (m, 1H, ArH), 7.49 – 
7.59 (m, 4H, ArH), 7.88 – 7.98 (m, 3H, ArH); 13C NMR (100 MHz, CDCl3): δ 55.70 (OCH3), 55.77 
(OCH3), 59.51 (OCH3), 60.55 (C-3), 61.86 (C-4), 94.71, 122.39, 125.12, 125.22, 125.81, 126.29, 
126.37, 127.06, 128.50, 128.73, 130.01, 131.89, 133.33, 133.49, 134.30, 135.96, 153.21 (ArC), 164.17 
(C=O); HRMS (M++Na): C26H23NO4NaS requires 468.1245 found 468.1269 
3.1.8.9 1-(3,4,5-Trimethoxyphenyl)-3,4-di(thiophen-2-yl)azetidin-2-one (18) was obtained from 2-
(thiophen-2-yl)acetyl chloride and 3,4,5-trimethoxy-N-(thiophen-2-ylmethylene)aniline (8f) as a brown 
oil (6.7% yield); IR (KBr disk) νmax: 1755.61 cm-1 (C=O); 1H NMR (400 MHz, CDCl3): δ 3.78 (s, 6H, 
2xOCH3), 3.81 (s, 3H, OCH3), 4.68 (d, 1H, J=2 Hz), 5.23 (d, 1H, J=2 Hz), 6.67 (s, 2H, ArH), 7.06- 7.09 
(m, 1H, ArH), 7.08 (d, 1H, J=3.52 Hz, ArH), 7.23 -7.24 (m, 1H, ArH), 7.33 (m, 1H, ArH), 7.42 (m, 2H, 
ArH); 13C NMR (100 MHz, CDCl3): δ 56.07 (OCH3), 60.98 (C-3), 61.07 (C-4), 94.9, 98.33, 125.58, 
125.97, 126.20, 126.37, 127.41, 127.48, 133.44, 135.60, 140.69, 153.57 (ArC), 163.96 (C=O); HRMS 
(M++Na): C26H23NO4NaS requires  424.4889; found 424.0628 
3.1.9 General method II for β-lactam preparation: The appropriate imine (10 mmol) and acetyl 
chloride (10 mmol) were added to CH2Cl2 (50 mL) under nitrogen and the mixture was left stirring for 2 
hours. Triethylamine (10 mmol) was added dropwise. The mixture was left to stir overnight. The 
mixture was washed firstly with distilled water (50 mL) (twice) and then with saturated aqueous sodium 
bicarbonate solution (50 mL). The organic layer was dried by filtration through anhydrous sodium 
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sulfate. The organic layer containing the product was collected and reduced in vacuo. The pure product 
was isolated by flash column chromatography over silica gel (hexane: ethyl acetate gradient). 
3.1.9.1 4-(4-Methoxy-3-nitrophenyl)-3-thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(19) was obtained from 2-(thiophen-2-yl)acetyl chloride and (4-methoxy-3-nitrobenzylidene)(3,4,5-
trimethoxyphenyl)amine (8c) as a brown powder (48.4% yield); Mp: 123ºC; IR (KBr disk) νmax: 
1742.06cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.76 (s, 6H, 2xOCH3), 3.79 (s, 3H, 
OCH3), 4.00 (s, 3H, OCH3), 4.49 (d, 1H, J=2.5 Hz, H-3), 4.98 (d, 1H, J=2.5 Hz, H-4), 6.57 (s, 2H, 
ArH), 7.03 – 7.05 (m, 1H, ArH), 7.10 (d, 1H, J=3 Hz, ArH), 7.18 (d, 1H, J=8.52 Hz, ArH), 7.33 (d, 1H, 
J=5 Hz, ArH), 7.60 – 7.63 (dd, 1H, ArH), 7.94 (s, 1H, ArH); 13C NMR (100 MHz, CDCl3)  δ 55.78 
(OCH3), 56.31 (OCH3), 59.75 (C-3), 60.52 (OCH3), 62.92 (C-4), 94.48, 114.25, 123.13, 125.28, 125.66, 
127.07, 128.82, 130.78, 132.59, 134.56, 134.77, 139.45, 152.80 (ArC), 163.33 (C=O); HRMS (M++Na): 
C23H22N2O7NaS requires 493.1045; found 493.1047 
3.1.10 General method III for β-lactam preparation: The appropriate acetic acid (15 mmol) was 
refluxed for 30 minutes with triphosgene [bis(trichloromethyl) carbonate] (5 mmol) in dry CH2Cl2 (50 
mL). A solution of the appropriately substituted imine (10 mmol) in dry CH2Cl2 (10 mL) was added 
dropwise to the refluxing solution. Triethylamine (30 mmol) was added. The reaction mixture was 
heated at reflux for 5 hours and stirred at room temperature overnight. The mixture was washed firstly 
with distilled water (twice) (50 mL) and then with saturated aqueous sodium bicarbonate solution (50 
mL). The organic layer was dried over anhydrous sodium sulphate. The pure product was isolated by 
flash column chromatography over silica gel (hexane:ethyl acetate gradient). 
3.1.10.1 4-(4-Methoxyphenyl)-3-naphthalen-1-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (20) 
was obtained from 2-(naphthalen-1-yl)acetic acid and N-(4-methoxybenzylidene)-3,4,5-
trimethoxybenzenamine (8a) as a pale yellow crystalline powder (6.9% yield); Mp: 164ºC; IR (NaCl 
film) νmax: 1741.44 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.72 (s, 6H, 2xOCH3), 3.77 (s, 
3H, OCH3), 3.87 (s, 3H, OCH3), 4.78 (d, 1H, J=2.4 Hz, H-3), 4.98 (d, 1H, J=2.4 Hz, H-4), 6.63 (s, 2H, 
ArH), 7.00 (d, 2H, J=8.52 Hz, ArH), 7.36 – 7.46 (m, 6H, ArH), 7.77 (d, 1H, J= 7.04 Hz, ArH), 7.84 (d, 
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1H, J=8.52 Hz, ArH), 7.89 (d, 1H, J=8.04 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ 54.94 (OCH3), 
55.54 (OCH3), 60.51 (OCH3), 62.00 (C-3), 63.33 (C-4), 94.39, 114.30, 123.29, 123.82, 125.28, 125.58, 
125.96, 127.47, 128.00, 128.46, 128.97, 131.16, 131.21, 133.29, 133.44, 134.01, 153.05, 159.65 (ArC), 
165.27 (C=O); HRMS (M++Na): C29H27NO5Na requires 492.1787; found 492.1774 
3.1.10.2 4-(4-Methoxyphenyl)-3-naphthalen-2-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (21) 
was obtained from 2-(naphthalen-2-yl)acetic acid and N-(4-methoxybenzylidene)-3,4,5-
trimethoxybenzenamine (8a) as a white solid (2.5% yield); Mp: 150ºC; IR (NaCl film) νmax: 1739.65 
cm-1 (C=O, β-lactam); 1H NMR (600 MHz, CDCl3) δ 3.73 (s, 6H, 2xOCH3), 3.78 (s, 3H, OCH3), 3.84 
(s, 3H, OCH3), 4.45 (d, 1H, J=2.52 Hz, H-3), 4.94 (d, 1H, J=2.48 Hz, H-4), 6.64 (s, 2H, ArH), 6.95 – 
6.97 (m, 2H, ArH), 7.36 – 7.42 (m, 3H, ArH), 7.48 – 7.50 (m, 2H, ArH), 7.80 – 7.88 (m, 4H, ArH); 13C 
NMR (100 MHz, CDCl3) δ 55.41, 56.06 (OCH3), 61.00 (OCH3), 63.94 (C-3), 65.27 (C-4), 94.89, 
114.75, 125.04, 126.23, 126.52, 127.39, 127.74, 127.88, 128.97, 129.30, 132.14, 132.87, 133.48, 
133.76, 134.51, 153.55, 160.02 (ArC), 165.65 (C=O); HRMS M++Na): C29H27NO5Na requires 
492.1787; found 492.1790 
3.1.10.3 4-(4-Methoxyphenyl)-3-(1-methyl-1H-indol-2-yl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (22) was obtained from 2-(1-methyl-1H-indol-2-yl)acetic acid and N-(4-methoxybenzylidene)-
3,4,5-trimethoxybenzenamine (8a) as a yellow solid (11.9% yield); Mp: 77 – 78 ºC; IR (NaCl film) νmax: 
1747.66 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.75 (s, 6H, NCH3, OCH3), 3.80 (s, 3H, 
OCH3), 3.81 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 4.52 (d, 1H, J=2.0 Hz, H-3), 4.94 (d, 1H, J=2.0 Hz, H-
4), 6.66 (s, 2H, ArH), 6.99 (d, 2H, J=8.52 Hz, ArH), 7.17 (m, 2H, ArH), 7.29 (m, 1H, ArH), 7.40 – 7.42 
(m, 4H, ArH); 13C NMR (100 MHz, CDCl3) δ 32.34 (NCH3), 54.92 (OCH3), 55.56 (OCH3), 57.49 (C-
3), 60.52 (OCH3), 63.22 (C-4), 94.32, 107.51, 109.67, 114.21, 118.51, 119.16, 121.72, 126.33, 126.59, 
126.92, 129.36, 133.61, 133.90, 136.84, 153.07, 159.39 (ArC), 166.09 (C=O); HRMS (M++H): 
C28H29N2O5 requires 473.2076; found 473.2075 
3.1.10.4 3-Furan-3-yl-4-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (23) was 
obtained from 2-(furan-3-yl)acetic acid and N-(4-methoxybenzylidene)-3,4,5-trimethoxybenzenamine 
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(8a) as brown crystals (4.9% yield); Mp: 127ºC; IR (NaCl film) νmax: 1743.69 cm-1 (C=O, β-lactam); 1H 
NMR (400 MHz, CDCl3) δ 3.75 (s, 6H, 2xOCH3), 3.80 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.34 (d, 1H, 
J=2.5 Hz, H-3), 5.06 (d, 1H, J=2.5 Hz H-4), 6.35 (d, 1H, J=3.28 Hz, ArH), 6.41 (t, 1H, ArH), 6.62 (s, 
2H, ArH), 6.96 (d, 2H, J=4.52 Hz, ArH), 7.36 – 7.38 (m, 2H, ArH), 7.45 (d, 1H, J=0.76 H, ArH); 13C 
NMR (100 MHz, CDCl3) δ 55.38 (OCH3), 56.05 (OCH3), 58.67 (C-3), 60.97 (OCH3), 61.43 (C-4), 
94.93, 108.75, 110.69, 114.68, 127.37, 128.82, 133.75, 134.58, 142.86, 147.50, 153.53, 160.03 (ArC), 
163.38 (C=O); HRMS (M++H): C23H24NO6 requires 410.1604; found 410.1605 
3.1.10.5 4-(4-Methoxyphenyl)-3-thiophen-3-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (24) was 
obtained from 2-(thiophen-3-yl)acetic acid and N-(4-methoxybenzylidene)-3,4,5-
trimethoxybenzenamine (8a)  as a off-white powder (19.2% yield); Mp: 130ºC; IR (KBr disk) νmax: 
1750.82 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.74 (s, 6H, 2xOCH3), 3.79 (s, 3H, 
OCH3), 3.85 (s, 3H, OCH3), 4.35 (d, 1H, J=2.52 Hz, H-3), 4.87 (d, 1H, J=2.52 Hz, H-4), 6.61 (s, 2H, 
ArH), 6.96 – 6.98 (m, 2H, ArH), 7.09 – 7.11 (m, 1H, ArH), 7.29 – 7.30 (m, 1H, ArH), 7.36 – 7.40 (m, 
3H, ArH); 13C NMR (100 MHz, CDCl3) δ 54.93 (OCH3), 55.56 (OCH3), 60.09 (OCH3), 60.52 (C-3), 
62.89 (C-4), 94.34, 114.25, 122.01, 125.85, 126.42, 126.85, 133.33, 134.20, 153.05, 159.52 (ArC), 
164.89 (C=O); HRMS (M++Na): C23H23NO5NaS requires 448.1195; found 448.1189 
3.1.10.6 4-(4-Methoxyphenyl)-3-(5-methylthiophen-2-yl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (25) was obtained from 2-(5-methylthiophen-2-yl)acetic acid (5b) and N-(4-methoxybenzylidene)-
3,4,5-trimethoxybenzenamine (8a) as a brown oil (3.1% yield); IR (NaCl film) νmax: 1736.68 cm-1 (C=O, 
β-lactam); 1H NMR (400 MHz, CDCl3) δ 2.50 (s, 3H, CH3), 3.74 (s, 6H, 2xOCH3), 3.84 – 3.87 (m, 6H, 
2xOCH3), 4.41 (d, 1H, J=2.5 Hz, H-3), 4.89 (d, 1H, J=2.5 Hz, H-4), 6.60 (s, 2H, ArH), 6.67 – 6.71 (m, 
3H, ArH), 6.86 (d, 1H, ArH, J=3.52 Hz), 6.96 (d, 2H, ArH, J=8.76 Hz); 13C NMR (100 MHz, CDCl3) δ 
15.36 (CH3), 55.38 (OCH3), 56.04 (OCH3), 60.51 (OCH3), 60.97 (C-3), 61.00 (OCH3), 64.62 (C-4), 
94.93, 114.70, 125.30, 125.73, 127.26, 128.89, 133.73, 140.03, 153.45, 153.52, 160.02 (ArC), 164.71 
(C=O); HRMS (M++H): C24H26NO5S requires 440.1532; found 440.1535 
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3.1.10.7 3-Benzo[b]thiophen-2-yl-4-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(26) was obtained from 2-(benzo[b]thiophen-2-yl)acetic acid (5a) and N-(4-methoxybenzylidene)-3,4,5-
trimethoxybenzenamine (8a) as a white solid (5.6% yield); Mp: 118ºC; IR (NaCl film) νmax: 1747.58 
cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.75 (s, 6H, 2xOCH3), 3.81 (s, 3H, OCH3), 3.86 
(s, 3H, OCH3), 4.56 (d, 1H, J=2.0 Hz, H-3), 5.02 (d, 1H, J=2.0 Hz, H-4), 6.63 (s, 2H, ArH), 6.99 (d, 2H, 
J=8.52 Hz, ArH), 7.35 – 7.41 (m, 5H, ArH), 7.76 (d, 1H, J=7.04 Hz, ArH), 7.83 (d, 1H, J=7.52, ArH); 
13C NMR (100 MHz, CDCl3) δ 54.95 (OCH3), 55.60 (OCH3), 60.35 (OCH3), 60.53 (C-3), 63.60 (C-4), 
94.48, 114.33, 121.82, 121.99, 123.16, 124.10, 124.17, 126.84, 128.16, 133.13, 134.20, 136.49, 139.11, 
153.10, 159.68 (ArC), 163.36 (C=O); HRMS (M++H): C27H26NO5S requires 476.1532; found 476.1537 
3.1.10.8 4-(3-((tert-Butyldimethylsilyl)oxy)-4-methoxyphenyl)-3-(thiophen-3-yl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (27) was obtained from 2-(thiophen-3-yl)acetic acid and  [3-(tert-
butyldimethylsilanyloxy)-4-methoxybenzylidene](3,4,5-trimethoxyphenyl)amine (8b) as a brown oil and 
was desilylated to form 29 without further purification (crude yield: 79.5%). 
3.1.11 General method IV for preparation of β-lactams 28 – 29: To a solution of the appropriately 
protected phenol (10 mmol) in THF (50 mL) was added 1.5 equivalents of 1M tetrabutylammonium 
fluoride. The solution was stirred in an ice-bath for 15 minutes. The reaction mixture was diluted with 
ethyl acetate (100 mL) and quenched with 10% HCl (100 mL). The layers were separated and the 
aqueous layer was extracted with ethyl acetate (2 x 50 mL). The organic layer was then washed with 
water (100 mL) and brine (100 mL) and was dried with sodium sulphate. The pure product was isolated 
by flash column chromatography over silica gel (hexane: ethyl acetate gradient). 
3.1.11.1 4-(3-Hydroxy-4-methoxyphenyl)-3-thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (28) was obtained from 4-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)-3-(thiophen-2-yl)-1-
(3,4,5-trimethoxyphenyl)azetidin-2-one (14) as brown crystals (1.3% overall yield); Mp: 113-114ºC; IR 
(KBr disk) νmax: 1721.07cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.76 (s, 6H, 2xOCH3), 
3.80 (s, 3H, OCH3), 3.94 (s, 3H, OCH3), 4.48 (d, 1H, J=2.5 Hz, H-3), 4.87 (d, 1H, J=2.5 Hz, H-4), 5.75 
(s, 1H, OH), 6.62 (s, 2H, ArH), 6.89 – 6.95 (m, 2H, ArH), 7.01 – 7.03 (m, 3H, ArH), 7.31 – 7.32 (m, 
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1H, ArH); 13C NMR (100 MHz, CDCl3) δ 55.58 (OCH3), 55.61 (OCH3), 59.70 (OCH3), 60.51 (C-3), 
64.07 (C-4), 94.50, 110.60, 111.46, 117.36, 124.86, 125.28, 126.87, 129.54, 133.18, 134.15, 135.68, 
145.93, 146.53, 149.32, 153.06 (ArC), 163.90 (C=O); HRMS (M++Na): C23H23NO6SNa requires 
464.1144; found 464.1124 
3.1.11.2 4-(3-Hydroxy-4-methoxyphenyl)-3-thiophen-3-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (29)  was obtained from 4-(3-((tert-butyldimethylsilyl)oxy)-4-methoxyphenyl)-3-(thiophen-3-yl)-1-
(3,4,5-trimethoxyphenyl)azetidin-2-one (27) as a pale pink solid (18.6% yield); Mp: 151 – 152ºC; IR 
(KBr disk) νmax: 1739.65 cm-1 (C=O, β-lactam), 3187.91 cm-1  (-OH); 1H NMR (400 MHz, CDCl3) δ 
3.76 (s, 6H, 2xOCH3), 3.80 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 4.34 (d, 1H, J=2.2, H-3), 4.82 (d, 1H, 
J=2.2 Hz, H-4), 5.77 (s, 1H, OH), 6.63 (s, 2H, ArH), 6.89 – 6.96 (m, 2H, ArH), 7.02 (m, 1H, ArH), 7.09 
– 7.11 (m, 1H, ArH), 7.29 – 7.31 (m, 1H, ArH), 7.39 – 7.41 (m, 1H, ArH); 13C NMR (100 MHz, CDCl3) 
δ 56.05 (OCH3), 56.09 (OCH3), 60.48 (C-3), 60.98 (OCH3), 63.32 (C-4), 94.87, 111.06, 111.98, 117.81, 
122.44, 126.33, 126.85, 130.43, 133.78, 134.65, 146.39, 146.93, 153.53 (ArC), 165.28 (C=O); HRMS 
(M++Na): C23H23NO6SNa requires 464.1144; found 464.1153 
3.1.12 4-(3-Amino-4-methoxyphenyl)-3-thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one 
(30): To 4-(4-methoxy-3-nitrophenyl)-3-thiophen-2-yl-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (19) 
(10 mmol) in glacial AcOH (5 mL) was added metallic zinc dust (10 equiv.). The mixture was stirred for 
6 days at room temperature under nitrogen until TLC indicted formation of product. The residue was 
filtered through Celite and was extracted with dichloromethane. The amino compound was isolated 
using a hexane and ethyl acetate gradient column. and was obtained as a brown residue (48.5% yield); 
IR (NaCl film) νmax: 1749.94 cm-1 (C=O, β-lactam); 1H NMR (400 MHz, CDCl3) δ 3.76 (s, 6H, 
2xOCH3), 3.80 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 4.49 (d, 1H, J=2 Hz, H-3), 4.83 (d, 1H, J=2.52 Hz, 
H-4), 6.64 (s, 2H, ArH), 6.78 – 6.81 (m, 3H, ArH), 7.03 – 7.05 (m, 1H, ArH), 7.08 – 7.09 (m, 1H, ArH), 
7.29 – 7.31 (m, 1H, ArH) ; 13C NMR (100 MHz, CDCl3) δ 55.59 (OCH3), 56.07 (OCH3), 60.13 (C-3), 
60.98 (OCH3), 64.84 (C-4), 94.93, 110.53, 111.56, 116.43, 125.25, 125.70, 127.31, 129.34, 133.81, 
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134.50, 136.36, 136.96, 147.76, 153.50 (ArC), 164.60 (C=O); HRMS (M++H): C23H25N2O5S requires 
441.1484; found 441.1471 
3.1.13 General procedure for synthesis of β-lactams 31 – 34. A solution of 4-(4-methoxyphenyl)-1-
(3,4,5-trimethoxyphenyl)azetidin-2-one 9 (2.5 mmol) in dry THF (20 mL) was stirred at -78 ˚C under a 
nitrogen atmosphere. A 2M lithium diisopropylamide (5 mmol) solution was added quickly and the 
mixture was stirred for 5 minutes at -78 ˚C. A solution of the appropriate aldehyde (3.75 mmol) in dry 
tetrahydrofuran (5 mL) was added slowly to the reaction mixture. The reaction was stirred at -78 ˚C for 
30 minutes after which the reaction mixture was allowed to heat up to room temperature. It was poured 
into a saturated sodium chloride solution (50 mL). This solution was extracted with ethyl acetate, the 
organic layer was separated and was dried over anhydrous sodium sulphate. The pure product was 
isolated by flash column chromatography over silica gel (hexane: ethyl acetate gradient).  
3.1.13.1 3-(Furan-3-yl-hydroxymethyl)-4-(4-methoxyphenyl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (31) was obtained as a yellow oil by reaction of furan-3-
carbaldehyde and 4-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (9) in 50.2% yield; IR 
(NaCl film) νmax: 1740.12 cm-1 (C=O, β-lactam), 3453.40 cm-1 (-OH); 1H NMR (400 MHz, CDCl3) δ 
3.44 – 3.49 (m, 1H, H-3), 3.77 (s, 6H, 2xOCH3), 3.81 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 4.84 (d, 0.6H, 
J=2.52 Hz, H-3), 5.08 (d, 0.4H, J=2 Hz, H-4), 5.14 (t, 0.6H), 6.55 (m, 3H, ArH), 6.86 – 6.91 (m, 2H, 
ArH), 7.18 – 7.25 (m, 2H, ArH), 7.39 – 7.41 (m, 1.3H, ArH); 13C NMR (100 MHz, CDCl3) δ 53.00 
(OCH3), 54.83 (C-4), 54.88 (OCH3), 55.51 (OCH3), 55.59 (OCH3), 55.83 (OCH3), 57.32 (C-3), 59.98 
(OCH3), 60.48 (OCH3), 63.31, 64.52, 64.79, 65.14 (CH), 94.26, 94.32, 108.16, 108.81, 114.02, 114.12, 
125.25, 125.83, 126.97, 127.00, 128.48, 128.81, 133.15, 133.97, 139.00, 139.81, 143.19, 143.23, 
153.00, 159.17, 159.39 (ArC), 164.79 (C=O), 164.81 (C=O); HRMS (M++Na): C24H25NO7Na requires 
462.1529; found 462.1509 
3.1.13.2 3-(Hydroxythiophen-2-yl-methyl)-4-(4-methoxyphenyl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (32) was obtained as a light yellow powder from thiophene-2-
carbaldehyde and 4-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (9) in 12.4% yield by 
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the above method; Mp: 96ºC; IR (KBr disk) νmax: 1745.90 cm-1 (C=O, β-lactam), 3436.73 cm-1 (-OH); 
1H NMR (400 MHz, CDCl3) δ 3.53 – 3.56 (m, 1H, H-3), 3.71 (s, 6H, 2xOCH3), 3.77 – 3.81 (m, 6H, 
2xOCH3), 4.83 (d, 0.6H, J=2.5 Hz, H-4), 5.20 (d, 0.4Hz, J=2.5 Hz, CH), 5.41 (d, 0.6H, J=6.52 Hz, CH), 
5.61 (d, 0.4H, J=3.92 Hz, CH), 6.55 (d, 2H, J=6 Hz, ArH), 6.83 – 6.89 (m, 2H, ArH), 6.92 – 6.96 (m, 
1H, ArH), 7.00 – 7.02 (m, 0.6H, ArH), 7.14 – 7.17 (m, 2.5H, ArH), 7.26 – 7.29 (m, 1H, ArH); 13C NMR 
(100 MHz, CDCl3) δ 54.81 (OCH3), 54.86 (OCH3), 55.51 (C-4), 55.54, 55.59, 55.63, 57.54 (C-3), 60.49 
(OCH3), 65.50, 65.94, 66.04, 68.02 (CH), 94.31, 94.39, 94.63, 113.58, 113.91, 114.04, 123.55, 124.55, 
124.91, 125.34, 126.42, 126.44, 126.85, 127.05, 128.26, 128.80, 133.09, 133.12, 133.92, 134.01, 
143.48, 144.59, 152.96, 153.00, 153.05, 159.11, 159.33 (ArC), 164.64 (C=O); HRMS (M++Na): 
C24H25NO6NaS requires 478.1300; found 478.1292 
3.1.13.3 3-(Hydroxythiophen-3-yl-methyl)-4-(4-methoxyphenyl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (33) was obtained from thiophene-3-carbaldehyde and 4-(4-
methoxyphenyl)-1-(3,4,5-trimethoxy-phenyl)azetidin-2-one (9) as a yellow powder (43.6% yield) by the 
above method; Mp: 69ºC; IR (NaCl film) νmax: 1745.08 cm-1 (C=O, β-lactam), 3438.10 cm-1 (-OH); 1H 
NMR (400 MHz, CDCl3) δ 2.85 (broad s, 0.4H), 3.01 (broad s, 0.4H), 3.48 – 3.52 (m, 1H, H-3), 3.71 (s, 
6H, 2xOCH3), 3.77 (m, 6H, 2xOCH3), 4.82 (d, 0.6H, J=2 Hz, H-4), 5.08 (d, 0.6H, J=2 Hz, H-4), 5.25 (d, 
0.5H, J=6 Hz), 5.45 (s, 0.5H),  6.55 (s, 2H, ArH), 6.81 – 7.02 (m, 2H, ArH), 7.02 (m, 1H, ArH), 7.15 – 
7.17 (m, 2H, ArH), 7.28 – 7.41 (m, 2H, ArH); 13C NMR (100 MHz, CDCl3) δ 54.80 (OCH3), 54.87 
(OCH3), 55.56 (C-4), 55.59, 57.44 (C-3), 59.22, 60.49, 65.12, 65.64, 66.34, 66.45, 67.96 (CH), 76.81, 
94.28, 94.34, 94.60, 113.59, 113.91, 114.07, 120.70, 122.41, 125.00, 125.97, 126.14, 126.19, 126.72, 
126.84, 128.48, 128.89, 133.20, 133.91, 133.96, 141.61, 142.25, 152.99, 153.05, 159.01, 159.32 (ArC), 
164.97 (C=O), 165.53 (C=O); HRMS (M++Na): C24H25NO6NaS requires 478.1300; found 478.1282 
3.1.13.4 3-[Hydroxy-(5-methylthiophen-2-yl)-methyl]-4-(4-methoxyphenyl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (34) was obtained by reaction of 5-methylthiophene-2-carbaldehyde 
and 4-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (9) as a white powder (16.5% yield) 
by the above method; Mp: 186ºC; IR (KBr disk) νmax: 1736.68 cm-1 (C=O, β-lactam), 3500 cm-1 (-OH); 
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1H NMR (400 MHz, CDCl3)  δ 2.48 (s, 3H, CH3), 2.79 (s, 1H, OH), 3.53 – 3.55 (dd, 1H, H-3), 3.73 (s, 
6H, 2xOCH3), 3.78 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 4.83 (d, 0.8H, J=2.52 Hz, H-4), 5.19 (d, 0.2H, 
J=2 Hz, CH), 5.31 (d, 0.8 Hz, J=6.56 Hz, CH), 5.50 (s, 0.2H), 6.56 (s, 2H, ArH), 6.65 (m, 1H, ArH), 
6.87 – 6.95 (m, 3H, ArH), 7.17 – 7.20 (m, 1H, ArH), 7.29 (s, 1H, ArH); 13C NMR (100 MHz, CDCl3)  δ 
14.95 (CH3), 54.86 (OCH3), 55.54 (OCH3), 57.61 (C-3), 60.50 (OCH3), 65.34 (C-4), 68.21 (CH), 94.30, 
113.94, 114.04, 124.41, 125.02, 126.90, 128.38, 133.20, 140.24, 140.82, 153.01 (ArC), 163.54 (C=O); 
HRMS (M++Na): C25H27NO6NaS requires 492.1457; found 492.1473 
3.1.14 General procedure for oxidation of alcohols 32 and 33: Pyridinium chlorochromate (10 
mmol) was suspended in anhydrous dichloromethane (15 mL). The appropriate alcohol (32, 33) (15 
mmol, 1.5 equiv.) was dissolved in anhydrous dichloromethane (20 mL) and was added to the 
pyridinium chlorochromate suspension. The solution became briefly homogenous before depositing the 
black insoluble reduced reagent and was stirred for a further 2 hours. The reaction mixture was then 
diluted with 5 volumes of anhydrous ether. The solvent was decanted and the black residue was further 
washed with ether until the entire oxidised product was removed. The solvent was removed in vacuo 
and the product was isolated by flash column chromatography over silica gel using a hexane: ethyl 
acetate gradient elution. 
3.1.14.1 4-(4-Methoxyphenyl)-3-(thiophene-2-carbonyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (35) was prepared from 3-(hydroxythiophen-2-yl-methyl)-4-(4-methoxyphenyl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (32) as a yellow powder (27.3% yield); Mp: 123 ˚C; IR (KBr disk) 
νmax: 1751.87 cm-1 (β-lactam -C=O), 1655.95 cm-1 (C=O); 1H NMR (400 MHz, CDCl3) δ  3.73 (s, 6H, 
2xOCH3), 3.78 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 4.71 (d, 1H, J=2.52 Hz, H-3), 5.65 (d, 1H, J=2.52 
Hz, H-4), 6.57 (s, 2H, ArH), 6.96 (d, 2H, J=8.56, ArH), 7.21 – 7.23 (t, 1H, ArH), 7.41 (d, 2H, J=8.52 
Hz, ArH), 7.76 (d, 1H, J=4.52 Hz, ArH), 8.01 (d, 1H, J=4 Hz, ArH); 13C NMR (100 MHz, CDCl3) δ 
54.92 (OCH3), 55.41 (OCH3), 55.54 (C-4), 60.51 (OCH3), 68.20 (C-3), 94.39, 114.24, 127.20, 127.87, 
128.19, 132.94, 134.21, 134.58, 135.02, 142.35, 153.03 (ArC), 159.51 (C2=O), 159.61 (C2=O), 182.86 
(C=O); HRMS (M++Na): C24H23NO6NaS requires 476.1144; found 476.1141 
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3.1.14.2 4-(4-Methoxyphenyl)-3-(thiophene-3-carbonyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-
one (36) was prepared from 3-(hydroxythiophen-3-yl-methyl)-4-(4-methoxyphenyl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (33) as a white solid (18.6% yield); Mp: 143 – 144 ˚C; IR (KBr disk) 
νmax: 1735.14 cm-1 (β-lactam -C=O), 1673.80 cm-1 (C=O); 1H NMR (400 MHz, CDCl3) δ 3.74 (s, 6H, 
2xOCH3), 3.79 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 4.68 (d, 1H, J=2.44 Hz, H-3), 5.67 (d, 1H, J=2.44 
Hz, H-4), 6.58 (s, 2H, ArH), 6.96 (d, 2H, J=8.32, ArH), 7.37 – 7.43 (m, 3H, ArH), 7.70 (d, 1H, J=1 Hz, 
ArH), 8.43 – 8.44 (m, 1H, ArH); 13C NMR (100 MHz, CDCl3) δ 55.38 (OCH3), 55.69 (OCH3), 56.00 
(C-4), 60.98 (OCH3), 69.45 (C-3), 94.85, 114.70, 126.64, 127.12, 127.64, 128.45, 133.45, 134.69, 
135.34, 140.91, 153.51 (ArC), 160.05 (-C2=O), 160.25 (-C2=O), 184.60 (-C=O); HRMS (M++Na): 
C24H23NO6NaS requires 476.1144; found 476.1124 
3.1.15 General procedure for dehydration of alcohols 32 and 34: A solution of appropriate alcohol 
(32, 34) (10 mmol) and tosyl chloride (20 mmol) in dry pyridine (50 mL) was heated at reflux for 5 
hours under a nitrogen atmosphere. After cooling, ice/water (50 mL) was added and the mixture was 
extracted twice with chloroform (50 mL). The combined organic extracts were washed twice with dilute 
hydrochloric acid (50 mL) and once with water (50 mL), dried with anhydrous sodium sulfate and 
solvent evaporated in vacuo.  The pure product was isolated by flash column chromatography over silica 
gel (hexane: ethyl acetate gradient). 
3.1.15.1 (Z)-4-(4-Methoxyphenyl)-3-thiophen-2-ylmethylene-1-(3,4,5-trimethoxyphenyl)azetidin-
2-one (37) was prepared from 3-(hydroxythiophen-2-yl-methyl)-4-(4-methoxyphenyl)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (32) in 30.0% yield as a yellow oil; IR (KBr disk) νmax: 1721.18 cm-1 (-
C=O); 1H NMR (400 MHz, CDCl3) δ 3.77 (s, 6H, 2xOCH3), 3.80 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 
5.37 (s, 1H, H-4), 6.45 (s, 1H, CH), 6.68 (s, 2H, ArH), 6.95 (d, 2H, J=9.04 Hz, ArH), 7.08 – 7.10 (m, 
1H, ArH), 7.39 – 7.42 (m, 2H, ArH), 7.45 (d, 1H, J=4.52 Hz, ArH), 7.71 (d, 1H, J=3.52 Hz, ArH); 13C 
NMR (100 MHz, CDCl3) δ 54.90 (OCH3), 55.54 (OCH3), 60.53 (OCH3), 62.01 (C-4), 93.96, 114.09, 
120.91, 127.51, 127.93, 128.23, 128.96, 131.16, 133.70, 136.99, 137.60, 153.06 (ArC), 159.67 (C=O), 
159.82 (C=O); HRMS (M++Na): C24H23NO5NaS requires 460.1195; found 460.1189 
 35 
3.1.15.2 (Z)-4-(4-Methoxyphenyl)-3-(5-methylthiophen-2-ylmethylene)-1-(3,4,5-
trimethoxyphenyl)azetidin-2-one (38) was prepared from 3-[hydroxy-(5-methylthiophen-2-yl)-
methyl]-4-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one (34) as a brown oil (9.0% 
yield); IR (KBr disk) νmax: 1725.19 cm-1 (-C=O); 1H NMR (400 MHz, CDCl3) δ 2.54 (s, 3H, CH3), 3.77 
– 3.84 (m, 12H, 4xOCH3), 5.35 (s, 1H, H-4), 6.38 (s, 1H, CH), 6.68 – 6.74 (m, 2H, ArH), 6.94 – 6.96 
(m, 2H, ArH), 7.35 – 7.41 (m, 3H, ArH); 13C NMR (100 MHz, CDCl3) δ 15.69 (CH3), 55.35 (OCH3), 
56.05 (OCH3), 56.17 (OCH3), 58.67 (OCH3), 62.43 (C-4), 94.33, 94.93, 114.34, 114.52, 114.67, 118.58 
, 121.85 (-CH-), 126.19, 127.37, 128.39, 128.89, 132.28, 134.29, 135.59, 136.49, 145.21, 153.51 (ArC), 
160.08 (C=O), 160.51 (C=O); HRMS (M++H): C25H26NO5S requires 452.1532; found 452.1527 
3.2 Biochemistry: Experimental methods 
3.2.1 MTT assay procedure 
All assays were performed in triplicate for the determination of mean values reported. Compounds 
were assayed as the free bases isolated from reaction. The human breast tumour cell line MCF-7 was 
cultured in Eagles minimum essential medium in a 95%O2/5% CO2 atmosphere with 10% fetal bovine 
serum, 2mM L-glutamine and 100 µg/mL penicillin/streptomycin. The medium was supplemented with 
1% non-essential amino acids. MDA-MB-231 cells were maintained in Dulbecco’s Modified Eagle’s 
medium (DMEM), supplemented with 10% (v/v) Fetal bovine serum, 2mM L-glutamine and 100 µg/mL 
penicillin/streptomycin (complete medium). Cells were trypsinised and seeded at a density of 2.5 x 104 
cells/mL in a 96-well plate and incubated at 37oC, 95%O2/5% CO2 atmosphere for 24 h. After this time 
they were treated with 2 µL volumes of test compound which had been pre-prepared as stock solutions 
in ethanol to furnish the concentration range of study, 1 nM–100 µM, and re-incubated for a further 72 
h. Control wells contained the equivalent volume of the vehicle ethanol (1% v/v). The culture medium 
was then removed and the cells washed with 100 µL phosphate buffered saline (PBS) and 50 µL MTT 
added, to reach a final concentration of 1 mg/mL MTT added. Cells were incubated for 2 h in darkness 
at 37oC. At this point solubilization was begun through the addition of 200 µL DMSO and the cells 
maintained at room temperature in darkness for 20 min to ensure thorough colour diffusion before 
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reading the absorbance. The absorbance value of control cells (no added compound) was set to 100 % 
cell viability and from this graphs of absorbance versus cell density per well were prepared to assess cell 
viability using GraphPad Prism software59. 
3.2.2 Cytotoxicity assay using murine mammary epithelial cells 
Mammary glands from 14-18 day pregnant CD-1 mice were used as source and primary mammary 
epithelial cell cultures were prepared from these. Mammary epithelial cells were isolated as described by 
us previously.24 The isolated mammary epithelial cells were seeded at two concentrations. After 24 
hours, they were treated with 2 µL volumes of test compound which had been pre-prepared as stock 
solutions in ethanol to furnish the concentration range of study, 1 nM–100 µM, and re-incubated for a 
further 72 h. Control wells contained the equivalent volume of the vehicle ethanol (1% v/v). The 
cytotoxicity was assessed using alamar blue dye as reported previously.60 
3.2.3 Tubulin polymerization:  Tubulin polymerisation was carried out using a kit supplied by 
Cytoskeleton.  It is based on the principal that light is scattered by microtubules to an extent that is 
proportional to the concentration of the microtubule polymer. Compounds that interact with tubulin will 
alter the polymerisation of tubulin, and this can be detected using a spectrophotometer. The absorbance 
at 340nm at 37°C is monitored. The experimental procedure of the assay was performed as described in 
version 8.2 of the tubulin polymerisation assay kit manual61. 
3.3 Stability studies for compounds 13, 16, 17 and 18: Analytical high-performance liquid 
chromatography (HPLC) stability studies were performed using a Symmetry® column (C18, 5 µm, 
4.6×150 mm), a Waters 2487 Dual Wavelength Absorbance detector, a Waters 1525 binary HPLC pump 
and a Waters 717plus Autosampler.   Samples were detected at wavelength of 254 nm.   All samples 
were analysed using acetonitrile (80%): water (20%) as the mobile phase over 10 min and a flow rate of 
1 mL/min.   Stock solutions are prepared by dissolving 5mg of compound in 10 mL of mobile phase.   
Phosphate buffers at the desired pH values (4, 7.4, and 9) were prepared in accordance with the British 
Pharmacopoeia monograph 2010.   30 µL of stock solution was diluted with 1 mL of appropriate buffer, 
shaken and injected immediately. Samples were withdrawn and analysed at time intervals of  t=0 min, 5 
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min, 30 min, 60 min, 90 min, 120 min and 21 hours. Retention times were 13: 2.70 mins; 16: 3.75 mins; 
17: 3.74 mins; 18: 3.75 mins. 
3.4 Computational Procedures: For ligand preparation, all compounds were built using 
ACD/Chemsketch v10 to generate SMILES. A single conformer from each string was generated using 
Corina v3.4 and ensuring Omega v2.2.1 was subsequently employed to generate a maximum of 50 
conformations of each compound. For the receptor preparation, the PDB entries 1SA0 were downloaded 
from the Protein Data Bank (PDB). All waters were retained in both isoforms. Addition and 
optimisation of hydrogen positions for these waters was carried out using MOE 2007.09 ensuring all 
other atom positions remained fixed. Using the reported X-ray structure of tubulin co-crystallised with a 
colchicine derivative, DAMA-colchicine (PDB entry – 1SA0)51, possible binding orientations of the β-
lactam ligands were probed with the docking program FREDv2.2.3 (Openeye Scientific Software)62. 
Docking was carried out using FREDv2.2.3 in conjunction with the PLP scoring function. 3D ligand 
conformations were enumerated using CORINAv3.4 (Molecular Networks GMBH)63 followed by 
generation of multiple conformations using OMEGAv2.2.1 (Openeye Scientific Software)64. Each 
conformation was subsequently docked and scored with PLP as outlined previously14. The top binding 
poses were refined using the LigX procedure (MOE - Chemical Computing Group)65 together with 
Postdock analysis (SVL script; MOE) of the docked ligand poses.  
 
3.5 X-ray crystallography: The X-ray crystallography data for crystals was collected on a Rigaku 
Saturn 724 CCD Diffractometer. A suitable crystal was selected and mounted on a glass fiber tip and 
placed on the goniometer head in a 123K N2 gas stream. The data set was collected using Crystalclear-
SM 1.4.0 software and 1680 diffraction images, of 0.5° per image, were recorded. Data integration, 
reduction and correction for absorption and polarization effects were all performed using Crystalclear-
SM 1.4.0 software. Space group determination, structure solution and refinement were obtained using 
Crystalstructure ver. 3.8 and Bruker Shelxtl Ver. 6.14 software.66  
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Crystal Data for 11 (cis): C104H108N4 O20, MW 1733.94 (4 molecules).  Monoclinic, Space group P-1; 
a = 12.364(4), b= 13.084(4), c = 14.956(4)A˚, α = 82.867(11)o , β = 72.242(7)o, γ  = 84.107(12) o ; U = 
2280.9) A˚; Z = 1; Dc = 1.262Mg m-3; m = 0.087 mm-1;  Range for data collection = 1.12–25.00; 
Reflections collected 35367, Unique Reflections 8025 [Rint= 0.0486]; Data/restraints/parameters 
8025/0/587; Goodness-of-fit  on F2 1215; R indices (all data) = R1 = 0.0728, wR2 = 0.1442; Final R 
indices [I > 2s(I)] = R1 = 0.0642, wR2 = 0.1393. CCDC deposition no. 778106. 
Crystal Data for 11 (trans): C104H108N4 O20, MW 1733.94 (4 molecules).  Monoclinic, Space group 
P21/c; a = 11.538(3), b= 12.295(3), c = 18.953(4)A˚, α = γ = 90o, β = 123.08(12) o ; U = 2252.8(9) A˚; Z 
= 1; Dc = 1.278 Mg m-3; m = 0.088 mm-1;  Range for data collection = 1.12–25.00; Reflections 
collected 17982, Unique Reflections 3955 [Rint= 0.0441]; Data/restraints/parameters 3955/0/295; 
Goodness-of-fit  on F2 1244; R indices (all data) = R1 = 0.0674, wR2 = 0.1195; Final R indices [I > 
2s(I)] = R1 = 0.0616, wR2 = 0.1195. CCDC deposition no. 778108. 
Crystal Data for 12: C124H116N4 O20, Formula MW 1982.21 (4 molecules); Monoclinic, Space group 
P21/c; a = 10.349(3), b= 9.828(3), c = 26.547(8)A˚, α = γ = 90o, β = 110.277(10) o ; U = 2532.8(13) A˚; 
Z = 1; Dc = 1.300 Mg m-3; m = 0.088 mm-1;  Range for data collection = 1.12–25.00; Reflections 
collected 30080, Unique Reflections 4457 [Rint= 0.0652]; Data/restraints/parameters 4457/0/338; 
Goodness-of-fit  on F2 1222; R indices (all data) = R1 = 0.0789, wR2 = 0.1389; Final R indices [I > 
2s(I)] = R1 = 0.0835, wR2 = 0.1410.CCDC deposition no. 778107.  
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Supplementary Information Available: NCI60 cell-line data for β-lactam 13, HPLC purity data for 
target azetidinone compounds, chiral separation chromatograms for β-lactams 13 and 28, additional 
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molecular modeling for β-lactam 28 and cytotoxicity data for 2a and 28 in murine epithelial cells at 
50,000 cells/mL.  
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Figure, Scheme and Table captions 
Figure 1. Structures of small molecule tubulin-binding agents 
Figure 2a. Ortep representation of the X-ray crystal structure of β-lactam 11 (cis isomer) drawn with 
50% thermal ellipsoids 
Figure 2b. Ortep representation of the X-ray crystal structure of β-lactam 11 (trans isomer; 2 
enantiomers shown with relative stereochemistry) drawn with 50% thermal ellipsoids 
Figure 3. Ortep representation of the X-ray crystal structure of β-lactam 12 drawn with 50% thermal 
ellipsoids 
Figure 4: Antiproliferative effect of 2a and 3-(3-thienyl)-β-lactams 13 and 29 in MCF-7 human breast 
cancer cells. 
MCF-7 cells were seeded at a density of 2.5 x 104 cells per well in 96-well plates and left for 24 hours to 
allow the cells to adhere to the surface of the wells. A range of concentrations (0.01 nM-50 µM) of the 
compound were added in triplicate and the cells left for 72 hours. Control wells contained the equivalent 
volume of the vehicle ethanol:DMSO (70%:30%) (1% v/v). An MTT assay was performed to determine 
the level of anti-proliferation. The values represent the mean ± S.E.M (error values) for three 
experiments performed in triplicate.  
Figure 5. Cell viability in healthy murine epithelial cells  
Mouse mammary epithelial cells were harvested from mid- to late- pregnant CD-1 mice and cultured. 
The isolated mammary epithelial cells were seeded at two concentrations. After 24 hours, they were 
treated with 2 µL volumes of test compound which had been pre-prepared as stock solutions in ethanol 
to furnish the concentration range of study, 1 nM–100 µM, and re-incubated for a further 72 h. Control 
wells contained the equivalent volume of the vehicle ethanol (1% v/v). The cytotoxicity was assessed 
using alamar blue dye. 
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Figure 6. Inhibition of tubulin polymerisation for β-lactam 28 
Effects of compound 28 on in vitro tubulin polymerisation. Purified bovine tubulin and GTP were 
mixed in a 96-well plate. The reaction was started by warming the solution from 4 oC to 37oC. Ethanol 
(1%v/v) was used as a vehicle control. The effect on tubulin assembly was monitored in a Spectramax 
340PC spectrophotometer at 340nm at 30 second intervals for 60 minutes at 37 oC. The graph shows one 
representative experiment. Each experiment was performed in triplicate. 
Figure 7. Comparison of the docked conformations of β-lactams 3a, 12 and DAMA-colchicine.  
12 is shown in green; 3a (left) and DAMA-colchicine (right) are colored by atom with oxygen red, 
nitrogen blue, carbon grey and sulfur yellow. Protein residues are not shown for clarity. 
Figure 8. Docked pose of β–lactam 28 in the colchicine-binding site of tubulin 
Docked pose of β–lactam 28 in the colchicine-binding site of tubulin (PDB entry 1SA0). Significant 
binding residues Thr 179, Lys 241 and Val 318 are indicated. Hydrogens are not shown for clarity. 
Coloured by atom: Grey (carbon); red (oxygen); blue (nitrogen); yellow (sulfur). Residue numbers are 
those used by Ravelli et al51. 
Figure 9. 2D representation of binding interactions of β-lactam 28 in the colchicine-binding site of 
tubulin  
2-D rendering of ligand–protein interactions using LigX module of MOE used to create docked 
structures of 28 in the colchicine-binding site of tubulin55. Residue numbers are those used by Ravelli et 
al51. 
Scheme 1. Synthesis of substituted acetic acids 5a, 5ba 
aReagents and conditions: (a) Diethyl ether, 0°C, 1 hour; (b) 20°C; (c) NaH, toluene, 50°C, 1 hour; (d) 
10M HCl, 50°C, 30 mins 
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Scheme 2. Synthesis of imines 8a – 8fa 
aReagents and conditions: EtOH, reflux, 3 h 
Scheme 3. Synthesis of β-lactams 10 - 27a 
aReagents and conditions: (a) SOCl2, CHCl3, reflux, 3 h; (b) (Route I) triethylamine, CH2Cl2, reflux, 3 
h; (c) (Route II) triethylamine, CH2Cl2, 18 h; (d) (Route III) triphosgene, triethylamine, anhydrous 
CH2Cl2, reflux, 5 h, 18 h; TBMDS = tert-butyldimethylchlorosilyl 
Scheme 4. Synthesis of phenolic azetidinones 28, 29a  
aReagents and conditions: (a) TBAF, THF, 0 ˚C, 15 min; TBMDS = tert-butyldimethylchlorosilyl 
Scheme 5. Synthesis of amino-substituted azetidinone 30a  
aReagents and conditions: (a) Zn, CH3CO2H, 7 days 
Scheme 6. Synthesis of azetidinones 9, 31-33a 
aReagents and conditions: (a) Zn, TMCS, benzene, microwave; (b) LDA, dry THF, -78°C; (c) 
Pyridinium chlorochromate, CH2Cl2, 2 h; (d) Tosyl chloride, pyridine, reflux, 5 h 
Table 1. Azetidin-2-one combretastatin A-4 analoguesa 
aRoutes for synthesis were: compounds 10 – 18: route I; compound 19: route II; compounds 20 – 27: 
route III; Route I: triethylamine, CH2Cl2, reflux, 3 h; Route II: triethylamine, CH2Cl2, 18 h; Route III: 
triphosgene, triethylamine, anhydrous CH2Cl2, reflux, 5 h, 18 h; bTBMDS = tert-
butyldimethylchlorosilyl 
Table 2. Antiproliferative activities of β-lactams in human MCF-7 breast cancer cells 
 43 
aIC50 values are half maximal inhibitory concentrations required to block the growth stimulation of 
MCF-7 cells. Values represent the mean ± S.E.M (error values x 10-6) for at least three experiments 
performed in triplicate.  
bThe IC50 value obtained for 2a in this assay is 0.0052 µM for MCF-7 which is in good agreement with 
the reported values for 2a using the MTT assay on human MCF-7 breast cancer cell line18, 47, 48, 67  
Table 3. Antiproliferative activities of β-lactams in human MDA-MB-231 breast cancer cells 
aIC50 values are half maximal inhibitory concentrations required to block the growth stimulation of 
MDA-MB-231 cells. Values represent the mean ± S.E.M (error values x 10-6) for at least three 
experiments performed in triplicate.  
bThe IC50 value obtained for 2a in this assay is 0.043 µM for MDA-MB-231 which is in good agreement 
with the reported values for 2a using the MTT assay on the human MDA-MB-231 breast cancer cell 
line68, 69  
Table 4: Standard COMPARE Analysis of β-lactam 13a 
 
a The target set was the standard agent database and the target set endpoints were selected to be equal to 
the seed end points. Standard COMPARE analysis was performed. Correlation values are Pearson 
correlation coefficients. Vincristine sulfate and rhizoxin appear at different concentrations as they have 
been tested by the NCI at multiple concentration ranges  
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